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a,f Clotting factor subscript a represents activated factors; 
subscript f represents fragmented clotting factors 
following activation
ADP Adenosine 5'-diphosphate
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PTT Partial thromboplastin time
RVV Russell's viper venom
SRBC Sheep red blood cells
VBS Veronal-buffered saline
VLDL Very low density lipoproteins
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I ABSTRACT
Carrageenans are a group of galactan sulphates derived from marine 
Rhodophyceae. These polymers have been shown to exert a variety of 
pharmacological effects, several of which involve alterations in both immune 
and haemostatic responses. Carrageenans were studied for the following 
reasons:
1. To observe the effects of defined carrageenan fractions on blood co­
agulation using plasma obtained from polysaccharide treated and 
untreated rats. Both in vitro and ex vivo samples were then subjected 
to amidolytic and functional clotting assays. Results obtained 
suggest that carrageenan is able to inhibit the activity of Factor 
XII, Factor I and thrombin. Unlike the known activities of the anti­
coagulant heparin, carrageenan activity was noted in the absence
and presence of antithrombin III. The efficacy of carrageenan 
fractions to exert their particular anticoagulant response may reflect 
the ability of these polymers through their polyelectrolyte nature to 
form macromolecular complexes with respect to plasma proteins, thus 
neutralising their effectiveness in the clotting cascade.
2. Activation of the coagulation pathway also results in the activation 
of the fibrinotytic response. This activation can take place as a 
result of Factor II-dependent activation. Results obtained for the 
fibrinolytic response indicate that carrageenan did inhibit the 
fibrinolytic pathway when tested iii vitro. However, plasma samples 
obtained from carrageenan treated animals were found to have enhanced 
fibrinolytic activity.
3. The kallikrein-kinin pathway, like fibrinolysis, may be triggered 
through Factor XII activation. In vitro results suggest that 
carrageenan inhibits prekallikrein activation while ex vivo an 
initial potentiation was observed.
4. In the formation of a haemostatic plug, blood platelets play an 
essential role. The carrageenan per se in vitro had no direct 
effect on blood platelets. In the presence of aggregating agents 
adenosine 5’-diphosphate and thrombin,carrageenan inhibits the 
platelet aggregation response. Platelet-rich plasma obtained from 
carrageenan treated rats suggests that the galactan sulphate may 
induce thrombocytopenia. Platelets from carrageenan treated rats 
were observed to have a reduced response to adenosine 5’-diphosphate 
and thrombin-induced platelet aggregation.
5. Carrageenan-lipoprotein effects were investigated to correlate lipo­
protein levels with blood coagulation. Results suggest that 
macroion complex formation between lipoprotein lipase receptors
and carrageenan may result in a release of the lipase into the 
blood stream.
6. Finally, the immunosuppressive effect of carrageenan on the rat 
model was investigated. Preliminary studies suggest that the 
polyelectrolyte nature of the carrageenan may influence its role 
as an immunosuppressive agent.
I I  IN TR O D U C TIO N
1. CARRAGEENANS
1.1 Structure and properties
Carrageenan is the name given to a galactan sulphate of high 
molecular weight extracted from marine algae such as Chondrus crispus. 
This alga is also known as carrageenin, "Irish moss" or "carragheen 
moss" from Carragheen, Waterford in Ireland. The name carragheen, 
to designate the extract from Chondrus crispus, was first used by 
Stanford in 1862. The term carrageenan is more recent and was adopted 
by several authors after 1950 (American Chemical Society).
Carrageenans are isolated by aqueous extraction from various 
members of marine Rhodophyceae. The principal species commercially 
harvested are illustrated in Fig. 1.1.1. The polysaccharide structure 
comprises alternating a-(l-*3) , |3-(l->4) linked D-galactopyranose units. 
Carrageenans are highly sulphated with an ester sulphate content 
estimated 20-40% by dry weight.
In 1953 Smith and Cook showed that carrageenan extracted from 
CL crispus could be fractionated to yield lambda (X-)  and kappa (K-) 
carrageenan as- characterised by different solubilities in aqueous 
solution.
K-Carrageenan was that fraction precipitated from aqueous 
solution by the addition of potassium chloride up to a concentration 
of 0.25M. The fraction that remained in solution under the above 
conditions was designated X-carrageenan.
1 .
Figure 1.1.1
CLASS
ORDER
FAMILY
GENUS
SPECIES
CLASSIFICATION OF RHODOPHYCEAE
Rhodophyceae
Gigartinales
Gigartinaceae Solieriaceae Hypneaceae
Gigartina Chondrus Eucheuma Hypnea
G. stellata C. crispus E. spinosum H. musciformis
G. pistillata C. ocellatus E. cottonii
G. acicularis 
G. radula
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K-Carrageenan is composed of sulphated D-galactose and 3,6-anhydro-
D-galactose residues in approximately equimolar concentrations having
5a branched structure with molecular weight between 1.8 - 3.2 x 10 
daltons (Smith, Cook and Neal, 1954; Smith, O ’Neil and Perlin, 1958).
The X-carrageenan fraction was found to consist almost entirely of 
sulphated D-galactose with a molecular weight range between 4 - 7 x
510 daltons (Smith, O ’Neil and Perlin, 1958).
One other structure, iota (l-) carrageenan was found in C^. crispus 
in small quantities. 1-Carrageenan may be a precursor of K-carrageenan 
by the enzymic formation of an anhydrogalactose ring due to sulphate 
elimination (Peat, 1981).
The principal source of commercial carrageenan is C_. crispus.
This species yields both k - and X-carrageenan fractions and forms 
the basis of a multi-million pound industry.
1.2 The molecular architecture of carrageenans
Commercially isolated fractions of carrageenans have been extensively 
characterised in the laboratory and their chemical composition reviewed 
by Yaphe (1959), Rees (1961) and Percival (1972). From these studies 
it has been found that K-carrageenan may be represented by the 
idealised structure illustrated, Fig. 1.2.1. It is composed of a-(l+3)- 
linked D-galactopyrano-4-sulphate and B-(l+4)-linked 3,6-anhydro-D- 
galactopyranose units (Anderson, Dolan and Rees, 1968), with the a-(1+3) 
glycosidic and B-(l+4) glycosidic bonds alternating. Similarly, X- 
carrageenan exhibits heterogeneity and Rees (1969) suggested that 
the name X-carrageenan be reserved for material with the idealised 
structure composed of a-(1+3)-linked D-galactopyranose-2-sulphate and 
B-(1+4)-linked D-galactopyranose-2 ,6-disulphate, Fig. 1.2.1.
3 .
F i g u r e  1 . 2 . 1
Idealised structures of lambda, iota and kappa carrageenan
I-carrageenan
2-sulphate
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T h e  i d e a l i s e d  s t r u c t u r e  o f  l - c a r r a g e e n a n  m a y  b e  r e p r e s e n t e d  a s
shown in Fig. 1.2.1. The polymer has a disaccharide repeat unit of 
a-(l->3)-linked D-galactopyranose-4-sulphate and (3-(1^ -4)-linked 3,6- 
anhydro-D— galactopyranose-2-sulphate (Anderson, Dolan and Rees,
1968). Physical-chemical analysis of macromolecular extracts 
revealed the existence of chemical heterogeneity within individual 
species.
1.3 Chemically related mammalian polysaccharides
The galactan sulphates isolated from the seaweed are not unique 
and similar polymers have been extracted from a variety of organisms, 
These polymers, named glycosaminoglycans (GAGS), are primarily found 
in mammals and have a wide range of functions from providing physical 
support to a possible participation in blood clotting.
One such GAG is heparin, a long unbranched polysaccharide comprised 
of repeat units of glucosamine 2,6-disulphate and iduronide-2-sulphate 
(Casu et al., 1979), Figure 1.3.1. Sulphate and/or carboxyl groups 
present on the disaccharide unit make the chains strong polyanions at 
pH 7.4 and this results in some of its anticoagulant activity (Rees, 
1975). Unlike other GAGS, heparin is not a structural component, but 
occurs as an intracellular component in skin, lung,liver, gastric mucosa 
and umbilical cord. With respect to its commercial importance,heparin is 
isolated from bovine liver capsule and pig gastric mucosa.
Mammalian GAGS and polysaccharides from red algae exhibit many 
similarities in chemical and physical properties and an obvious 
inference is that, in at least some of their pharmacological effects, 
carrageenans mimic the actions of their mammalian counterparts.
5 .
F i g u r e  1 . 3 . 1
Idealised structure of heparin
6 .
1 . 4  P h y s i c a l  p r o p e r t i e s  o f  c a r r a g e e n a n s
1.4.1 Chemical structure
Carrageenans, with the exception of A-carrageenan, form helices 
in solution (McKinnon, Rees and Williamson, 1969). In the case of 
1-carrageenan, the chains are linked by inter-chain hydrogen bonding 
with the sulphate esters positioned on the outside of the helix 
(Williamson, 1970; Morris jet , 1978). The flexibility of this polymer 
is restricted to rotations around the four glycosidic bond angles and 
the 3,6-anhydro-D-glycosidic bond angles. The 3,6-anhydro-D-galacto- 
pyranose residues increase flexibiltiy of the polymer when in solution. 
K-Carrageenan forms a triple helix structure and in the formation of a 
matrix, straight chain A-like regions occur. K-Carrageenan forms the 
most viscous solution of the three types investigated. A-Carrageenan, 
however, forms a rigid straight chain and forms a less viscous solution.
Criteria such as the freedom of rotation, chain-chain interaction 
and ionic radius of the cations involved in the overall stucture of 
the gel matrix may influence the physiological and chemical properties 
of these polymers (Kindness, 1979).
1.4.2 Gel formation
As previously mentioned some carrageenans form helices under 
certain conditions of temperature and concentration. Such interactions 
can act as tie points to give a three dimensional gel network (Fig.
1.4.2.1). Should such a gel network occur in vivo then water and ion 
retention may occur. It may also mediate in the passage of molecules 
in and out of the cells in the manner of an ion exchange molecular 
sieve (Rees, 1969, 1972).
7 .
F i g u r e  1 . 4 . 2 . 1
Idealised gel network formation
oo
Random coil Helix formation Gel network
One important type of gel interaction is that with proteins.
This is of considerable relevance to the food industry and may offer 
an insight into the physiological effects of carrageenans. The 
properties of glycosaminoglycans and their influence on protein, ion
t l  ff
and water binding have been reviewed by Lindahl and Hook (1978).
1.5 Carrageenans as food additives
The use of carrageenans as food additives dates back many years 
to when seaweed was pulverised with milk to give a jelly-like food 
(Sauvageau, 1920). However, since 1937 carrageenan has been produced 
and sold as a food emulsifier and stabiliser on a commercial scale 
(Institute of Food Technologists Panel, 1973).
Due to the results of research carried out on the pharmacological 
effects of high concentrations of carrageenan, the World Health 
Organisation’s Expert Committee on Food Additives recommended in 1969 
that daily intake of carrageenan should not exceed 50 mg kg \  per 
day. The concentration of carrageenan required to stabilise foods 
ranges from 0.005 to 1.2% on a dry weight basis and thus the 
intake per individual is far below the recommended level.
Carrageenans have been used as emulsifiers, stabilisers and 
thickeners because of their ability to stabilise proteins, especially 
milk proteins (Hansen, 1966; Hansen and Lin, 1968; Lin, 1977), in 
foods such as indicated in Fig. 1.5.1.
1.6 Pharmacological effects of carrageenans
1.6.1 Absorption of carrageenans from the gastro-intestinal tract
Since the molecular weight of carrageenans used in food preparation 
is high,it was hoped that the polymer would not be absorbed through the
9.
Figure 1.5.1
CARRAGEENAN APPLICATIONS
Gelling Agent Milk jellified milk 
acidified milk 
puddings
aerated desserts
Water low calorie jams 
jellied fruits 
water gels 
meat aspics 
pet food 
air freshners
Thickening Agent Milk dessert creams 
custard 
yoghurt
Water cream soup 
tomato ketchup 
cosmetics 
toothpaste
Stabilisers Milk chocolate 
ice creams 
whipped creams
Water mayonnaise 
salad dressing 
squash
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intestinal wall. To date, the exact nature of carrageenan absorption
is unclear. The addition of carrageenan to the diet of monkey 
(Beattie et^  jal. , 1976; Abraham, Goldberg and Coulson, 1972; Grasso 
et al., 1973), pig (Poulsen, 1973), rat (Nilson and Wagner, 1959; 
Hawkins and Yaphe, 1965; Grasso et^  aT., 1973), mouse (Grasso et al., 
1973) and hamster (Grasso et fQ., 1973) resulted in carrageenan being 
found in faeces.
Work carried out by Nilson and Wagner (1959) using rats indicated 
that a carrageenan level of above 10% of dry diet retarded growth and 
resulted in liver abnormalities. Anderson and Soman (1966) showed 
that high molecular weight carrageenan was not absorbed through the 
gut of the guinea pig and could not be detected in the blood or 
urine. Further studies by Watt and Marcus (1969), in the same species, 
suggested that high molecular weight carrageenan caused ulceration 
of the caecum and colon. Similar results were observed with rabbits 
(Grasso jet aT. , 1973) .
Results would appear to be greatly differing; however, the 
outcome of these experiments may be related to the types of food 
stuffs normally consumed by the experimental animal and thus may 
reflect the influence of the endogeneous gut flora. Large macro­
molecules are known to be absorbed through neonatal and foetal small 
intestine (Freeman and Kim, 1978). Long-term feeding of carrageenan 
was found to affect rat foetal development (Collins, Blank and Prew, 
1977).
In the human intestine, bacteria with the ability to break down 
carrageenan may exist. Bacteria having a carrageenolytic effect have 
been found in the intestine and this may be a direct effect of the 
usage of carrageenan in food (Yaphe and Baxter, 1956; Weigl and
11.
Yaphe, 1966a,b).
3Carrageenan fragments with mean molecular weights ranging from 4 x 10 -
42 x 10 daltons were commercially prepared for the treatment of peptic 
and duodenal ulcers in humans. It was demonstrated that carrageenan 
had no adverse effect on the human colon over an extended period of 
2 years (Bonfils, 1970). Ingested carrageenan was found to have a 
lowering effect on blood cholesterol levels in chickens and rats 
(Fahrenbach, Riccardi and Grant, 1966; Ershoff and Wills, 1962). In 
this instance, the carrageenan may have caused a shift from low density 
lipoprotein (the density of lipoprotein involved in atherosclerosis), 
to high density lipoproteins which are removed from the body by the 
liver.
Thus carrageenan has been found to have many, if conflicting, 
effects on physiological body functions of animals following ingestion. 
Results would suggest that the usage of carrageenan in food stuffs 
should be limited until the nature of long-term influences may be 
determined.
1.6.2 Toxicity of carrageenan
Wilson et a^. (1978) showed that an injection of 200 mg kg * 
of carrageenan into the rat peritoneal cavity resulted in toxicity.
The most toxic formation found was K-carrageenan which caused 
disseminated intravascular coagulation. Injection of the other 
carrageenan fractions, namely X- and i -carrageenan,also resulted in 
a toxic effect but to a lesser degree. Fowler, Simpson and Thomson
(1980) similarly showed that the administration of carrageenan to 
rats produced tissue damage with focal blanching of the liver and 
splenomegally evident post mortem.
The pharmacological effects of degraded carrageenan are controversial.
12.
1.6.3 Effects of carrageenan on blood clotting
In 1954 Ratnoff observed that plasma incubated with carrageenan 
and activated with thrombin took a prolonged time to clot depending 
on the concentration of carrageenan. Later, work by Hawkins and 
Leonard (1963) indicated that carrageenan and carrageenan fractions 
X- and K- prolonged plasma clotting time, X- being the more efficient 
inhibitor of clotting. Debate over the exact nature of carrageenan 
anticoagulant activity resulted. Experiments carried out by other 
workers showed that the anticoagulant activity of carrageenan may 
be mediated via early stages of the coagulation pathway (Anderson 
and Duncan, 1965). The fact that carrageenan activity was concentration- 
and structure-dependent was verified with high concentrations of 
carrageenan prolonging blood clotting time whilst low concentrations 
were procoagulant.
These studies were mainly carried out on human plasma samples and 
to date there is no clear evidence of exactly at what point of the 
coagulation cascade system carrageenan exerts its effects. Experimental 
work carried out by Kindness, Long and Williamson (1980a), illustrated 
that on human plasma test systems carrageenans were anticoagulant.
1.6.4 Inflammatory responses to carrageenan
The inflammatory response to carrageenan was first observed by 
Winter, Risley and Nuss (1962). Carrageenans are now used extensively 
as producers of oedema against which potential anti-inflammatory 
drugs are screened and evaluated (Rocha e Silva, 1970; Schorlemmer,
1977; Damns, 1980a; Labreque, Dore and Belanger, 1981). In experimental 
animals the hind paw receives a carrageenan dose subcutaneously, and the 
paw is then observed for swelling. Inflammation induced by carrageenan
13.
was found to be suppressed by soybean trypsin inhibitor as well as by 
the administration of Aprotonin (van Arman et al., 1965; Di Rosa and 
Sorrentino, 1968). Both these compounds inhibit activation of the 
kallikrein-kinin system,thus preventing the production of vasoactive 
peptides termed kinins which are known to mediate inflammation and 
pain production.
Di Rosa and Sorrentino (1970) showed that animals injected with 
carrageenan had decreased arterial blood pressure thus confirming kinin 
production. Carrageenan-induced hypotension was also found by Damus 
(1979) but this effect was not present in thrombocytopenic rats; 
thus it may be speculated that platelets are causally involved in the 
hypotensive response.
A considerable amount of work has been carried out in vitro to 
investigate the influence of carrageenans on blood platelets (McMillan, 
McIntyre and Gordon, 1979; Vargaftig et^  al., 1980; Deflandre and Damus, 
1980; Kindness, Williamson and Long, 1980b). Carrageenans have been 
shown to aggregate human and rabbit platelets in vitro (Gordon,
McIntyre and McMillan, 1977; Vargaftig, 1977; Kindness, Williamson and 
Long, 1980b). Thus the aggregation and release of platelet contents 
may contribute to inflammatory mechanisms.
14.
2. HAEMOSTATIC PATHWAYS
2.1 Introduction
Blood coagulation, whether in vivo or in vitro, occurs as a 
result of a cascade system involving the interaction of nearly a dozen 
proteins, and giving rise to the formation of network of fibrin.
Over the many years of research into the processes of blood 
clotting the proteins have been called by a variety of names. However, 
the International Committee on Haemostasis and Thrombosis allocated a 
Roman numeral to each of the components of the coagulation pathway 
(Figure 2.1.1).
The formation of a blood clot can be triggered by two pathways 
sharing a common junction at Factor X, and resulting in the formation 
of an insoluble fibrin clot, (Fig. 2.1.2). As can be seen from Fig.
2 .1.3, the intrinsic pathway arises from the activation of Factor XII 
without tissue damage having taken place. In contrast, activation 
of the extrinsic pathway is the direct result of damage to a blood 
vessel whereby tissue thromboplastin is released. Tissue thrombo­
plastin in conjuction with exposed collagen and Factor VII activates 
Factor X. The exact role of tissue thromboplastin is not known but 
the enzymically active groups responsible for Factor X activation 
appear to be located on Factor VII. Both pathways require the additional 
components of platelet phospholipid and plasma calcium in order to 
form the insoluble fibrin clot.
2.2 The intrinsic pathway of coagulation
The initiation of the intrinsic pathway involves the participation 
of a number of proteins and contact with a suitable surface. Identification
15.
Figure 2.1.1
CLOTTING FACTORS
Factor Number Synonym used
I Fibrinogen
II Prothrombin
III Tissue thromboplastin
IV Calcium ions
V Proaccelerin
VII Factor VII
VIII Antihaemophilic factor
IX Christmas factor
X Stuart factor
XI Plasma thromboplastin antecedent
XII Hageman factor
XIII Fibrin-stabilising factor
Prekallikrein Fletcher factor
H.M.W. Kininogen High molecular weight Kininogen,
Fitzgerald factor
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Figure 2.1.2
^vtrinsic pathway of coagulation
Tissue Thromboplastin
FactorVll— rom^*-> FacforVlla
r _2+Ca'
Factor X Factor Xa
Factor y Th r.Pmb ^  altered FactorV)
Ca2+r
Phospholipid^
Prothrombin Thrombin
Fibrinogen * Fibin monomer
FacforXIIl—■rom )^' n» Factor XIII a)
Cf+{
Fibrin polymer
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Figure 2.1.3
The intrinsic pathway of coagulation
Factor IX — »T Factor iXal
Factor VIII JtHPniHaltered Factor VI11")
CaH
Phospholipid )
|FactorX|—»lFactor Xa
Factory_thr°mbj.Qaltered FactorV)
Ca2j
Phospholipid J
Prothrombin ■^Thrombin
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of the proteins participating in the coagulation cascade arose from 
studies of individuals with familial bleeding tendencies.
The initial factor required for intrinsic coagulation is 
Factor XII, first isolated by Ratnoff and Colopy (1955). Hageman 
deficiency, a deficiency of Factor XII, was observed in individuals 
having a prolonged bleeding time. The site of synthesis of Factor XII 
is unknown; however patients with hepatic cirrhosis have decreased 
plasma concentrations (Saito et jQ., 1976).
Experimentally, activation of Factor XII occurs on contact with 
a large variety of negatively-charged surfaces such as glass or kaolin 
(Ratnoff and Rosenblum, 1958), collagen (Wilner, Nossel and LeRoy,
1968), platelet membranes (Walsh, 1972) and endothelial cells 
(Wiggins et^  al. , 1980). It has been proposed that the binding of 
Factor XII to a negatively-charged surface results in a conformational 
change in the molecule exposing the active site required for enzymic 
activity. This hypothesis was confirmed by circular dichroism spectro­
scopy (McMillin et al., 1974; Fair et; al., 1977).
Apart from solid phase activation of Factor XII on contact with 
negatively-charged surfaces, fluid phase activation occurs when 
Factor XII is in contact with proteinases such as kallikrein or plasmin, 
(Ogston, 1981; Donaldson and Harrison, 1982). This activation results in 
the proteolytic cleavage of Factor XII and the fragments produced have 
the property of converting prekallikrein to kallikrein (Kaplan and 
Austen, 1971; Cochrane and Wuepper, 1971). The clot-promoting activity 
of this active fragment is much less than that of the parent molecule 
(Revak et_ al., 1974). Debate exists as to whether cleavage of 
Factor XII is required for clot-promoting properties. In 1979, Ratnoff
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and Saito carried out experiments that indicated that there was no 
cleavage within the active Factor XII molecule. The alternative view, 
however, is that Factor XII activation requires cleavage within a 
disulphide loop to form a two chain molecule (Griffin, 1977; Meier 
et al., 1977).
Studies carried out on surface-bound Factor Xlla and the free fraction 
have shown differences in their ability to catalyse the cleavage of 
radiolabelled prekallikrein and Factor XI. Both were capable of 
catalysing the cleavage of and thereby activating prekallikrein but 
only the surface-bound molecule caused the cleavage of Factor XI.
Hence these results would indicate that initiation of the intrinsic 
pathway is a localised process occurring at the site of contact 
activation (Revak £t_ jil^  , 1978) .
Factor Xlla activates Factor XI; however,experiments by Schiffman 
and Lee (1974) showed that purified Factor Xlla and Factor XI could 
not induce clot promoting activity. It is now recognised that both 
prekallikrein and HMWK are required for the activation of Factor XI 
but the exact nature of their function has not yet been clarified 
(Donaldson, personal communication). These requirements for clot- 
promoting activity were recognised in patients deficient in prekalli­
krein (Hathaway, Belhasen and Hathaway, 1965) or HMWK (Saito et^  jQ. ,
1975).
HMWK accelerates activation of Factor XI by Factor Xlla, activation 
of prekallikrein by Factor XII and activation of Factor XII by kalli- 
krein (Griffin and Cochrane, 1976). Thus,it is thought that Factor 
Xlla and HMWK form a complex on a negatively-charged surface which 
induces a conformational change in the Factor XI, rendering it susceptible 
to proteolytic cleavage. The surface-bound Factor Xlla activates
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prekallikrein and Factor XI. The generated kallikrein then activates 
more Factor XII thus increasing the quantity of Factor XIla (Ogston, 
1981). Meier et^  a!L. (1977) found that kallikrein-activated Factor XII 
by positive feedback: HMWK did not aid Factor XII binding to a surface
but potentiated its ability to activate prekallikrein and Factor XI. 
Factor XIla did not require prekallikrein but HMWK was required for 
the interaction of Factor Xlla and Factor XI (Ratnoff and Saito, 1979).
Fujikawa et aJ. (1979) raised the possibility of an alternative 
pathway of Factor XII activation in which Factor XII would be readily 
activated by kallikrein in the presence of dextran sulphate, even 
in the absence of a surface such as kaolin. Once Factor XI has been 
activated,it converts the inactive precursor Factor IX to its active 
form. This process involves a proteolytic cleavage to reveal the 
active site.
Factor IX forms a complex with phospholipid, obtained in the 
form of a platelet surface, calcium ions, Factor VIII and inactive 
Factor X. The Factor VIII may be present in the circulating plasma 
or bound to the platelet surface. A deficiency of Factor VIII causes 
excessive bleeding and it is thought that Factor VIII is required for 
platelet adhesion to subendothelial tissue.
Factor IXa and Factor VIII are adsorbed onto the phospholipid 
surface in the presence of calcium and in this form activate Factor X. 
The phospholipid may provide a surface on which Factor IXa and Factor 
VII align themselves in a suitable conformation to activate Factor X. 
The calcium ions form positively-charged bridges between the negatively' 
charged phospholipid and proteinases (Baugh and Hougie, 1979).
Thrombin, which is present in small concentrations in the plasma,
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activates Factor VIII. If the concentration of thrombin increases, 
inactivation of Factor VIII occurs. This is an example of negative 
feedback where inhibition of the reaction prevents thrombotic 
tendencies (Ogston, 1981).
Factor Xa, acting in concert with phospholipid and calcium 
ions, activates Factor V which is converted to thrombin by proteolytic 
cleavage. Thrombin is the enzyme responsible for the conversion of 
fibrinogen to fibrin.
2.2.1 Thrombin-catalysed cleavage of fibrinogen to fibrin
Fibrinogen is a dimer composed of two symmetrical subunits linked
f t
by disulphide bridges, with two-fold symmetry (Blomback, Hessel and 
Hog, 1976). The half molecules each consist of three polypeptide 
chains (Aa, B|3, y), and the interchain disulphides occur as two clusters 
in the molecule, one in the N-terminal part and a similar cluster in 
the C-terminal area (Doolittle et a]L. , 1979) . Interchain disulphide
n
loops occur in C-terminal portions of all three chains (Blomback and
f t  t f
Blomback, 1972; Blomback, Hessel and Hog, 1976).
Factor Xa catalyses the cleavage of prothrombin to form active 
thrombin, a two chained molecule (Magnusson et al., 1976). Thrombin, 
like Factor X, Factor IV and Factor VII is dependent on vitamin K 
for its synthesis, and like Factor II, is synthesised in the liver. 
Vitamin K imparts the ability to adhere to phospholipid in the presence 
of calcium ions. Thus,a complex of Factor Xa, Factor VII and Factor II 
attaches itself to a phospholipid surface, probably platelet derived, 
via calcium ion bridges and the active enyzme thrombin is released 
from the phospholipid into the circulation CMagnusson et al., 1975).
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Thrombin acts on fibrinogen to form initially a linear polymer 
and then a branched polymer with resultant cleaved fibrinopeptides.
The last enzymic step in blood clotting centres around the strengthening 
of the fibrin-to-fibrin association by inter-molecular y-glutamyl-e- 
lysine bridges (Lorand, 1972). The fibrin-stabilising factor (Factor 
XIII) circulates as an inactive precursor which is converted to the 
active form in the presence of thrombin and calcium ions. The 
Factor XIII action results in the production of a cross-linked fibrin 
network (Lorand, 1972).
2.3 Regulation of haemostasis
The existence of control mechanisms within coagulation and 
platelet aggregation has been under investigation but a lot less is 
known about these systems than for contact activation.
Results from experiments on the enzymic action of thrombin on 
fibrinogen indicated that the blood possessed the ability to inactivate 
thrombin (Schmidt, 1892). The substance responsible was later found 
to be Antithrombin (Moravik, 1905). Research in this field progressed 
slowly and only in the last fifteen years have the clinical consequences 
of Antithrombin deficiency been elucidated (Egeberg, 1965).
Antithrombin (AT III) is one of the proteinase inhibitors of 
blood, inactivating all the clotting enzymes except Factor Vila. This 
inhibitory effect was found to be greatly accelerated in the presence 
of heparin, by a factor of 1000 (Quick, 1938).
AT III is a a -globulin and comparison of amino acid sequence 
reveals a relatively high degree of homology with a^-antitrypsin, 
suggesting the two inhibitors may have a common ancestry (Nordenman, 
Nystron and Bjork, 1977; Peterson et^  a^. , 1979). The binding of heparin
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to AT III is dependent on ionic strength and pH may occur at one
M t t
(Danielson and Bjork, 1978; Bjork et al., 1981), or two binding sites 
on the AT III molecule (Piepkorn, Lagunoff and Schmer, 1978). 
Fluorescence studies suggest a low molecular weight fraction of heparin 
binds to AT III in molar ratio 1:1, while high molecular weight
t l
fractions appear to have two binding sites (Nordenman and Bjork,
1978; Rosenberg et^  al^ , 1979).
The precise mode of heparin action on AT III is unknown but 
three models have been proposed. Heparin may bind to AT III, inducing 
a conformational change to facilitate thrombin binding. Once the 
thrombin is bound,the heparin is released and binds another AT III 
molecule (Rosenberg and Damns, 1973; Li, Fenton and Feinman, 1976; 
Marciniak and Gora-Maslak, 1982). Alternatively, heparin may bind to 
thrombin thus inducing a reaction with AT III (Machovich, Blasko 
and Palos, 1975). Lastly, heparin and thrombin may bind simultaneously 
to AT III and induce a conformational change whereupon heparin is
I t
released (Holmer, Soderstrom and Andersson, 1979).
AT III is also known to interact with other glycosaminoglycans, 
such as heparan sulphate and dermatan sulphate,but in each case a 
higher concentration of polysaccharide was required (Teien, Abilgaard
I I  I f
and Hook, 1976; Hatton, Berry and Regoeczi, 1978; Kindness, Long and 
Williamson, 1979). Heparan sulphate apparently functions in a 
heparin-like manner,whilst dermatan sulphate exerts its anticoagulant 
effect in a manner independent of AT III activity. In view of the 
presence of these compounds in the vascular wall, these findings 
suggest their importance as stationary anticoagulants at the endothelial 
surface (Hatton, Berry and Regoeczi, 1978).
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Relatively little is known about inhibitors other than AT III
and the glycosaminoglycans. The serine proteinase inhibitors in 
plasma tend to have broad specificity but vary in their affinity towards 
the various enzymes.
The antiproteinase a0-macroglobulin (a0-M) binds to enzymes 
without blocking their active sites, permitting the cleavage of small 
molecular substrates. Steinbuch, Blatrix and Josso (1966) showed that 
a -M inhibited the clotting activity of thrombin. Since then it has been 
shown that a„-M accounts for 25 per cent and AT III 70 per cent of 
total thrombin inhibiting action of plasma (Shapiro and Anderson,
1977; Josso, 1978). Thrombin inhibition is much more rapid in the 
presence of AT III than with Otg-M (Abildgaard, 1969).
The inactivation of thrombin by a - anti tryp sin occurs at a low rate 
provided the initial thrombin concentration is high but this effect 
is much weaker than that of AT III or a-M. As individuals with a 
deficiency of a^-antitrypsin have normal thrombin inhibitory activity 
in plasma and do not show a special tendency towards thrombosis, these 
in vitro anticoagulant effects appear to have little or no physiological 
relevance dji vivo.
An inhibitor of the activated first component of the complement 
system, Cl inhibitor, also inhibits several haemostatic enzymes of 
plasma: Factor Xlla (Forbes, Pensky and Ratnoff, 1970); kallikrein 
(Ratnoff et^  aT., 1969); Factor XIa (Forbes, Pensky and Ratnoff, 1970) 
and the fibrinolytic enzyme plasmin (Schreiber, Kaplan and Austen,
1973). Complexes between Cl inhibitor and the above proteinase 
excluding plasmin,have also been detected by Donaldson and Harrison 
(1982).
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The antiproteinases detailed above are required to regulate the
pathways associated with coagulation, inflammation and fibrinolysis.
It has been shown that negatively-charged galactan sulphates are 
capable of interacting with these antiproteinases and thereby may 
modify the physiological activities associated with the haemostatic 
response (Ratnoff, 1954; Kindness, Long and Williamson, 1981).
2.4 The kallikrein-kinin system
During contact activation of plasma, Factor XII binds to negatively- 
charged surfaces together with HMWK and prekallikrein. The HMWK 
circulates, complexed at least in part to prekallikrein or Factor XI 
(Mandle, Colman and Kaplan, 1976; Thompson, Mandle and Kaplan, 1977), 
and is instrumental in bringing both prekallikrein and Factor XI to 
the surface (Wiggins et al_. , 1977) . The orientation of Factor XII 
with prekallikrein leads to limited proteolytic cleavage of Factor 
XII and activation of both molecules, each serving as a substrate for 
the other (Weiss, Gallin and Kaplan, 1974). Cochrane and Revak (1980) 
concluded that contact activation of plasma may be divided into three 
phases; firstly, the activation of Factor XII by prekallikrein on 
the surface with HMWK acting as a cofactor orientating the molecules 
into the correct position for cleavage; secondly, this activation was 
followed by a rapid release of kallikrein into the fluid phase; 
finally,the continued conversion of prekallikrein to kallikrein 
by each surface-bound molecule of Factor XII.
Two forms of kininogen exist in plasma; these are low molecular 
weight kininogen (LMWK) and high molecular weight kininogen (HMWK)
(Kaplan, 1979). HMWK is cleaved by kallikrein to produce the vasoactive 
peptide bradykinin and other fragments (Kaplan, 1979; Nakayaso and
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Nagasaura, 1979). Bradykinin production may remove the cofactor for 
the conversion of prekallikrein to kallikrein and the conversion of 
Factor XII to Factor Xlla (Chan, Movat and Burrowes, 1979).
Plasma kallikrein has esterase activity and is inhibited by at 
least four different proteinase inhibitors, namely Cls inhibitor,
CU-M, AT III and possibly a,-antiproteinase (Spragg and Austin, 1977; 
Donaldson and Harrison, 1982; van der Graaf, Koedam and Bouma, 1983).
The kinins produced are involved in the inflammatory response, 
contraction of smooth muscle, dilation of blood vessels, increased 
vascular permeability, leucocyte migration and production of the 
pain sensation (Abe, 1981). Kinins are vasoactive substances which 
might contribute, together with prostaglandins, to the regulation 
of blood pressure through peripheral arteriole dilation (Abe, 1981).
The kallikrein-kinin system is essential in the inflammatory 
response and is closely associated with the immune response, facilitating 
the movement of macrophages and lymphocytes to the site of tissue 
damage (Schorlemmer, 1977).
The biological effects exerted by this pathway involve a close 
relationship with Factor XII, as illustrated in Figure 2 .8.1.
Consequently, the coagulation, fibrinolytic and inflammatory mechanisms 
share a focal point through the activation of Factor XII. This 
further displays the inter-dependence of physiological pathways in the 
maintenance of haemostasis.
2.5 Plasma fibrinolytic system
The formation of a fibrin clot at the site of tissue damage 
results in the activation of the fibrinolytic pathway. Plasminogen, 
the zymogen of plasmin, is adsorbed onto the surface of the fibrin
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network, together with activators that are present locally in the 
vessel wall or in the circulating blood (Moroz, 1980). Cells circulating 
in the plasma account for most of the fibrinolytic activity, having 
plasminogen associated with the cells surface (Todd, 1959; Moroz, 1980). 
Polymorphonuclear leucocytes are the major component of the cellular 
phase. They contain enzymes,such as cathespin G and elastase-like 
proteinase (Plow and Edington, 1978; Moroz, 1977) and possess surface 
receptors for fibrin (Sherman and Lee, 1977), capable of facilitating 
interaction with the substrate.
Polymorphonuclear leucocytes are observed in proximity to the 
endothelium in normal veins, and the presence of normal numbers of poly­
morphonuclear leucocytes protects against thrombosis (Stuart et^  al. , 
1977). Hence, these cells are functionally equipped, numerically 
adequate and appropriately situated for removal of physiological 
fibrin deposits.
The plasminogen molecule consists of two domains. One domain 
contains the active site whilst the other bears the binding region.
The active form of plasminogen is called Glu-plasminogen due to the 
residue of glutamine at the N-terminus. Cleavage of Glu-plasminogen 
results in the release of a small peptide from the N-terminus producing 
the lysine-containing residue called Lys-plasminogen. This partial 
degradation enhances activation of the enzyme and increases its 
affinity for fibrin (Thorsen, 1975) and for a0-antiplasmin (Wimen,
Lijnen and Collen, 1979). This is probably by exposure of the lysine- 
catalysing substrate binding site.
Plasminogen activators have proved difficult to isolate; however, 
Rijken et al. (1979) succeeded in the purification of an activator from
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human uterine tissue. It was established through antibody binding 
studies that this activator was derived from tissue (Rijken, 1980). 
Therefore, if both plasminogen and its activators are adsorbed onto 
the surface of fibrin then the activation of plasminogen will occur 
only in the presence of fibrin.
The fibrinolytic system may be activated by venous occlusion, 
strenuous exercise, stress, certain drugs and natural damage. Regulation 
of this pathway is essential to prevent haemorrhaging. The most 
significant plasmin inhibitor is a0-antiplasmin; it binds plasmin in 
a 1:1 molar stoichiometric complex devoid of proteinase activity 
(Moroi and Aoki, 1976; Wimen and Collen, 1977). The a -antiplasmina
inhibits plasmin and in addition decreases the binding of Lys-plasminogen 
to fibrin (Aoki, Moroi and Tackiya, 1978). A fast-acting plasxnin 
inhibitor has been purified from platelets and shows similarities 
to a0-antiplasmin both in structure and function (Sandbjerg-Hansen 
and Clemmensen, 1980).
Early attempts to characterise FDPs by immunoelectrophoresis 
established the similarity between degradation products X, Y, D and 
E formed in vitro (Fisher crt st^ . , 1967). More recently, immuno- 
absorption or physical methods have been used (Merskey et al_. ,
1980).
FDPs are known to influence the immune system and it has been 
shown that plasmin-induced FDPs increase leucocyte chemotatic 
activity and vascular permeability (Sueishi, Nano and Tanaka, 1981). 
Results from FDP administration to mice indicate inhibition of the 
immune system but the exact mechanism has not yet been fully elucidated.
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2.6 Platelets in blood coagulation
Platelets are small non-nuclear cells derived from megakaryocytes.
In the quiescent state,platelets contain organelles such as dense 
granules, alpha granules, lysosomes, peroxidases and mitochondria 
(Zucker, 1980).
The dense granules contain calcium, adenosine 5*-diphosphate 
(ADP), adenosine 5'-triphosphate (ATP), 5-hydroxytryptamine and possibly 
a^-antiproteinases (Holmsen, 1975). The granules are considered to 
contain platelet-derived coagulation factors including fibrinogen,
Factor V and platelet Factor VIII (Nurden and Caen, 1979; Zucker,
Brockman and Kaplan, 1979).
Lysosomes make up only a small portion of platelet organelles 
but contain a number of degradative enzymes such as cathepsin (Brentfield 
and Bainton, 1975; Ehrlich and Gordon, 1976). These degradative enzymes 
may be important in platelet phagocytic reactions (Niewiarowski, 1977).
Platelets are essential for haemostasis in several ways as they 
adhere to sites of tissue damage and to each other, to form a haemo­
static plug which helps restore the patency of the vessel. The platelet 
also provides the phospholipid required for some stages of the 
coagulation cascade, and finally the platelet releases presynthesised 
coagulation factors into the micro-environment ,thus promoting clot 
formation.
Activation of platelets may occur via specific receptors on the 
platelet surface for collagen, thrombin and ADP causing viscous metamorphosis, 
with possibly the release of cellular components. Activation of platelets 
also results in exposure of receptor sites on the platelet surface, 
for example, for fibrinogen (Bennett, Valaire and Burch, 1981). Platelet
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activation to form aggregates may also be associated with immune 
complex formation as would occur in some disease states (Clark 
et al., 1980).
Recent advances in platelet studies have suggested that platelets 
may undergo viscous metamorphosis without the release reaction occurring 
and that if these cells are left in_ vitro for one to two hours, the 
cells regain their normal shape (Kindness, personal communication). 
However, once the release reaction has occurred, the platelets 
disintegrate and are no longer able to reassociate (Mustard and Packham, 
1970).
In the platelet aggregation, thrombin appears to act on 
platelets by association with platelet component glycocalin (Ganguly 
and Gould, 1979; Okumura, Hasitz and Jamieson, 1978). Several 
investigators have characterised thrombin binding to platelets noting 
high and low affinity binding (Martin et^  aJ., 1976; Tam and Detwiler, 
1978). These differing affinities may represent two classes of 
thrombin platelet binding sites (Tam, Fenton and Detwiler, 1979).
Once membrane bound, thrombin potently induces platelet aggregation 
and secretion apparently by diverse mechanisms. When stirred with 
platelets,thrombin causes platelet aggregation and secretion of granule 
contents, while in the absence of stirring only secretion occurs 
(Mills and MacFarlane, 1976). At low concentrations of thrombin, 
platelet secretion may be mediated by prostaglandin endoperoxides 
and thromboxanes, while higher thrombin concentrations may elicit 
secretion even when cyclo-oxygenase is blocked and cyclic AMP levels 
are elevated (Charo, Feinman and Detwiler, 1977; Shuman, Botney and 
Fenton, 1979; Kindness, Long and Williamson, 1981). The biochemical
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basis of this type of platelet activation is not known but could
involve translocation of calcium across the membrane (Kinlough-
Rathbone et suL. , 1977) or release of lipophospholipid from membranes (Chignard
et al. , 1979; Gerrard et^  tijU , 1979). There is some evidence to suggest
that thrombin, perhaps generated on platelet surfaces, may be an
important factor in the mediation of collagen-induced platelet
aggregation in plasma (Nichols et eL. , 1980) .
2.7 Plasma lipoproteins
Plasma lipoproteins are the "vehicle” of lipids in the blood stream.
They are organised in such a way that they are able to carry water- 
insoluble lipids in an aqueous solution. The apolar lipid constituents 
of lipoproteins, triglyceride and esterified cholesterol, are organised 
in a core surrounded by a surface film made by cholesterol, phospholipid 
and proteins (Jackson, Morrisett and Gotto, 1976). The protein moiety 
of lipoprotein is heterogeneous and many different apoproteins have 
been identified (Schaefer et^  ^ 1., 1978). Lipoprotein synthesis takes 
place only in the intestine and liver. In particular, the liver 
synthesises very low density lipoprotein (VLDL) and high density lipo­
protein (HDL); the intestine synthesises chylomicrons, VLDL and HDL 
(Eisenberg, 1976).
The catabolism of plasma lipoproteins takes place by three 
different mechanisms. Lipid and protein exchange and/or transport, 
enzyme modification of lipoproteins and cellular uptake by means of 
high affinity receptors and non specific endocytosis (Smith, Pawnall 
and Gotto, 1978).
The exchange and transfer of lipids among lipoprotein classes 
is well known; however, the mechanism and quantitative aspects are still
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unclear (Smith, Pawnall and Gotto, 1978).
Lipoprotein lipase (LPL), hepatic lipase (HL) and lecithin 
cholesterol acyl transferase (LCAT) are recognised as the main effectors 
of the enzyme lipoprotein catabolism (Smith, Pawnall and Gotto, 1978).
LPL catalyses the hydrolysis of the triglycerides of chylomicrons and 
the VLDL at the vascular endothelium and by its action the lipoproteins 
are transformed to lipoprotein remnants (Redgrave, 1970; Robinson, 1970). 
Chylomicron remnants are sequestered by the liver where they suppress 
cholesterol biosynthesis (Nervi and Dietschy, 1975). VLDL remnants 
may either be sequestered by the liver or peripheral tissues; however, 
under normal circumstances, VLDL remnants are further catabolised 
to LDL (Sigurdsson, Nicoll and Lewis, 1975).
LCAT is synthesised in the liver and secreted into blood where 
it catalyses the esterification of cholesterol and a fatty acid derived 
from phosphatidycholine. VLDL and HDL are LCAT substrates and LCAT 
is involved with the regulation of cholesterol exchange between 
lipoprotein and tissues (Glomset and Noruin, 1973).
Catabolism of lipoprotein by peripheral cells occurs by interaction 
of lipoproteins with specific receptor sites (Mahley and Innerarity, 
1977). The action of LPL occurs at endothelial surfaces; it catalyses 
the hydrolysis of triglycerides of lipoproteins to form free fatty 
acids and glycerol.
2.8 Interrelationship of blood coagulation, kinin, complement and
fibrinolytic pathways
The coagulation, kinin, complement and fibrinolytic systems form 
an intricate defence mechanism against mechanical or biological invasion 
of the body. As each of these systems becomes more clearly understood,
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it becomes apparent that they should not be regarded as separate systems
but rather as interacting components of the overall defence mechanisms 
(Fig. 2.8.1).
Each system described previously is multi-component and involves 
the action of proteinases which are formed from circulating precursors. 
They also involve cascade sequences in which a small stimulus is 
amplified. Each system is partially controlled by a series of inhibitors 
which act either by destroying the activity of a component or neutralising 
one of the proteinases. Each of these attributes suggests close links to 
the coagulation mechanism. Examination of these systems suggests the 
presence of such links around the contact phase of blood coagulation, 
that is Factor XII, prekallikrein, HMWK and Factor XI.
The end product of this relationship is that a steady state of 
haemostasis is maintained with a fine balance between formation and 
break down of blood clots .
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Figure 2.8.1
Inter-relationship of blood coagulation, 
fibrinolysis and inflammatory reactions
FIBRINOLYSIS
f
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3. THE IMMUNE SYSTEM
3.1 The Immune response
The essence of immunity lies in the ability to distinguish self 
from non-self. It is upon the ability to make this distinction that 
the organism has built a biological defence system geared to fend off 
pathological invaders. The diversity of the immune response is reflected 
in the apparent ability of the organism to recognise and respond to 
a large number of intrusive foreign antigens.
The functions of one area of the immune system, the humoral 
response, are conducted by a series of white blood cells, macrophages 
and lymphocytes. The latter cells are present in two forms: thymus-
dependent (T) lymphocytes and thymus-independent, bone marrow-derived 
(B) lymphocytes. The cells of the humoral response work together, in 
ways that are not completely understood, to produce antibodies which 
are directed against the challenging antigen. These specific antibodies 
are released into the circulation by antibody-producing plasma cells.
The other aspect of immunity does not depend on secreted antibodies 
but rather on the direct action of antigen-specific lymphocytes. Cell- 
mediated immune responses rely on direct contact between target cells 
and effector lymphocytes, the latter being T cells (Katz, 1977).
Experiments, primarily by Glick, Chang and Japp (1956) and 
Cooper et^  al_. (1966) on the chicken and by Millar (1962) on the mouse 
showed that not all lymphocytes within an individual were functionally 
equivalent. By removing a particular lymphoid organ early in the 
development of the host, and then challenging with an antigen, the 
immune system was examined. These experiments led to the view that 
depletion of chicken B lymphocytes by bursectomy resulted in the
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inability to mount humoral immune responses (i.e. make antibody) 
without seriously affecting the cell-mediated immunity. Depletion of 
T lymphocytes by thymectomy resulted in the inability to mount both 
humoral and cell-mediated responses. The conclusions of these experi­
ments were that T and B cells must interact before antibody could 
be produced in response to a specific antigen and that B cells were 
directly responsible for the synthesis and secretion of antibody, 
while T cells provided essential regulatory signals (Claman, Chaperon 
and Triplett, 1966).
A more refined picture of how T and B cells work to mount a 
humoral response came from experiments by Mitchison (1971). These 
experiments were designed to determine whether or not T and B cells 
recognised the same or different determinants on a complex antigen.
This work used immunogenic carriers bearing specific haptens which were 
themselves antigenic but not immunogenic. To elicit an anti-hapten 
response they must be attached to an immunogenic substance. Thus, 
an injection of 2,-4’-dinitrophenol did not elicit a response but 
when attached to bovine serum albumin and injected, a response resulted. 
The antibodies produced then recognised and bound 2'-4’-dinitrophenol 
alone or when coupled to a number of other carriers. This "carrier" 
effect was a key piece of evidence implicating the recognition of two 
different determinants during the course of the humoral response. The 
critical experiment demonstrating that T cells recognised the carrier 
determinants was done by Raff (1970).
Each cell type associated with the immune response is now 
discussed in detail.
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3.2 6 cells
B cells are generally described as the antibody producing 
cells of the humoral immune response. These cells can be distinguished 
from T cells by a set of characteristic surface antigens and a 
distinct path of differentiation.
The membrane marker of the B lymphocyte is immunoglobulin. In 
1900 Ehrlich predicted that B cells contained many thousand copies 
of the same immunoglobulin molecule which served as specific receptors 
for antigen and harbingers of the antibodies which their plasma cell 
progency would ultimately secrete. These propositions were found 
to be correct by Moller (19 6 1)t and in 1970 Raff, Sternberg and 
Taylor demonstrated that immunoglobulin was found on some but not all 
lymphoid cells. They also found that any one cell produced only one 
immunoglobulin; whether the membrane immunoglobulin functions as an 
antigen receptor remains unanswered (Sato and Gefter, 1981).
Work by Ada and Byrt (1969) and Warner, Byrt and Ada (1970) 
established two facts in cellular immunology. Firstly, antigen reacts 
with specific lymphocytes capable of contributing to the immune 
response to that antigen only. Secondly, the reaction of antigen 
with specific B lymphocytes is through the receptor activity of their 
surface immunoglobulin. Expanding on these studies, Warner, Byrt 
and Ada (1970) determined that surface immunoglobulin acted as a 
vehicle for the antigen-lymphocyte interaction. While these experi­
ments did not offer definitive proof that the B cell receptor for antigen 
was surface immunoglobulin, they were certainly suggestive of the 
importance of possible B cell-antigen interactions.
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In 1974 Julius and Herzenberg used direct cell selection to 
show that in the course of an immune response to antigen X, antibodies 
produced late in the response bound antigen more tightly than anti­
bodies which appeared earlier. This may be due to preferential 
selection of B cells bearing high avidity receptors under conditions 
where antigen concentration is decreasing. This avidity increase can 
be used as a monitor for the progress of the immune response.
Individual B cells differ in their expression of surface 
characteristics and also have been found to differ from one another 
somewhat in their ability to make an immune response (Saito and 
Gefter, 1981). One of the most important functional differences 
between individual B cells is their relative dependence upon T cells 
in the successful production of antibody. As stated previously, the 
humoral response to most antigens required both T and B cell participation. 
Studies with T cell-deprived mice have demonstrated that these immuno- 
deficient animals are capable of producing antibodies to certain kinds 
of antigen, known as T-independent antigens (Scher et_ al., 1975). It 
is, however, not yet clear whether these groups of B cells represent 
different cell lineages or different stages of one cell lineage.
In the immune response, antigen binding results in the initiation 
of two distinct phenomena: proliferation of the appropriate B cell
clones and differentiation of those antigen-binding cells into 
antibody-secreting cells. This was demonstrated by the work of Nossel 
and Ada (1971) in which animals immunised with an antigen were found to 
contain 100- to 1000-fold more antigen-binding cells specific for 
the antigen than naive animals. Also, antigen-binding cells were 
themselves incapable of antibody production. Thus, antigen encounter 
and a family of appropriate cell-cell interactions, are responsible for
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expanding the population of lymphocytes reactive to the intruding 
antigen. They then induce lymphocyte maturation into plasma cells 
capable of delivering secreted antibodies into serum to inactivate 
the antigen.
3.3 T cells
The possibility that functionally distinct populations of T cells 
existed came from studies conducted by Cantor and Asofsky (1970, 1972) 
using antisera specific for lymphocyte antigens (Lyt 1, 2 and 3) 
believed to be expressed on the surface of T cells. Cantor and Boyse 
(1975) demonstrated that selective displays of Lyt antigens distinguished 
precursors of helper T cells (Lyt 1 and 2) from precursors of suppressor 
T cells (Lyt 2 and 3). A third population, bearing all three Lyt 
antigens, was designated as an immature population of T cells which had 
not been committed to either helper or suppressor activities.
It has been found that helper T cells are required to stimulate 
B cells to divide and to differentiate into antibody-secreting cells.
For conventional antigens, both the helper T cell and the B cell are 
specific for the same antigen although not necessarily for the same 
determinants. In experimental systems using hapten-bound carriers, 
the helper T cell is specific for the carrier whilst the B cell is 
specific for the hapten. Successful activation of an antibody response 
also involves the participation of macrophages. The T suppressor 
cell may influence this intricate network of interacting cells by 
altering the ability of the helper T cell, B cells or macrophages 
to function (Gershon and Kondo, 1971). That is, suppression could 
result by preventing macrophages from "presenting” antigen to T helper 
cells; by inhibiting B or T helper cell proliferation or by differen­
tiation; or by actively eliminating B or T helper cell clones. The
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action of T suppressor cells causes the animal to become tolerant to 
invading organisms. However, this phenomemon was found to be antigen- 
specific in that the recipient animal could still respond to a 
closely related antigen.
Studies carried out by Tada elb j^. (1974) showed that suppression 
of antibody formation was carrier-specific, suggesting that suppression 
could be directed at the T helper cell. They showed that an active 
soluble factor could be obtained from sonicated spleen cells or 
thymocytes of animals injected in such a way as to produce suppressor 
T cells. This "factor” mimics exactly the action of the suppressor 
T cells, and if injected prior to antigen stimulation, prevents anti­
hapten antibody formation. Taniguchi and Takuhisa (1980) reported 
that the "factor" is elaborated in response to the interaction of a 
specific antigen with a specific T cell. The target of the T,factor" 
is not a specific T helper cell but appears to be yet another T cell, 
that is, it elaborates an antigen-non-specific "factor". It was 
the second of these "factors" which resulted in the final suppression 
of antibody formation. The antigen-non-specific end point of this 
chain of reactions illustrates how a mono-specific suppressor cell 
could suppress all helper activity.
To determine the target cell at the end of the suppressor chain, 
experiments were carried out to eliminate the suppressor T cell popu­
lation (Herzenberg et al., 1976). This did not, however, result in 
immediate resumption of an antibody response. This was thought to 
be due to complete absence or total inactivation of the specific T 
helper cell population. In contrast, the B cell population in suppressed 
animals is perfectly functional and can be activated by presentation of 
appropriate active T helper cells.
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In summary, suppression is brought about by a cascade of 
events which involves several cell types and soluble substances 
which ultimately lead to the prevention of antibody formation. 
Suppressor cells and antigen are at the start of the cascade, and 
the target cell may be the T helper cell.
3.4 Macrophages and antigen presentation
The involvement of macrophages in the immune system was observed 
when it was shown that immune responses were enhanced when antigens 
were taken up by phagocytic cells but depressed when these cells 
were removed (Unanue and Askonas, 1968). These results led to the 
theory that the antigen must be "processed" by macrophages to 
stimulate lymphocytes.
The term macrophage describes a wide variety of phagocytic cells, 
present in a number of different tissues. The cells contain many 
lysosomes and surface receptors for both immunoglobulin and the 
third component of complement. The macrophage acts as an intermediary 
between free antigen and T helper cells, being recognised by the 
expression of a gene product called la present on the macrophage 
surface, specific for an antigen. Thus the essential requirements 
for T cell binding to macrophages are the antigen and la gene 
product specific for the antigen.
It was demonstrated by Rosenthal and Shevack (1973) that free 
antigen without macrophages, or macrophages alone, are not capable 
of activating T cells. If,however,macrophages were exposed to 
antigen and then the antigen washed off, the macrophage would still 
elicit an immune response. They also showed that animals incapable
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of responding to a particular non-specific antigen are defective in 
the ability of their macrophages to ’’present" that antigen to the 
T cells in an effective way.
Sprent (1980) showed the association of macrophages, T and B 
cells to be as follows: T helper cells which have receptors specific
for the antigen in association with the la molecule on the appropriate 
macrophage will only bind to and activate B cells bearing the same 
la molecule, resulting in B cell proliferation and maturation to 
give active immunoglobulins against the antigen. Thus B cells and 
macrophages present similar determinants to a reactive T cell although 
the acquisition of the antigen has been specific for the B cell and 
non-specific for the macrophage.
Activated macrophages release a variety of factors (Gery and 
Waksman, 1972) including lymphocyte-activating factor,which induces 
the appropriate T cells (but not B cells) to proliferate. Macrophages 
are stimulated to produce this factor by lipopolysaccharides or 
phytohaemagglutinin. The resting T cells exposed to this factor 
demonstrate an increased responsiveness to T cell mitogens (stimulators) 
such as concanavalin A or phytohaemagglutinin.
The failure of macrophages to process and present antigen is, 
as previously described, associated with the inability of the organism 
to mount an immune response against that antigen. This may result 
in the appearance of T suppressor cells (Pierres and Germain, 1978) .
Such T suppressor cells are specific for the antigen and can prevent 
any further response to that antigen even if macrophages are present.
It has been shown that T suppressor cells can bind free antigen 
while T helper cells require macrophage-antigen presentation. The 
failure of macrophages to take up antigen results in an excess of
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circulating antigen. The T suppressor cells would therefore also 
remain unresponsive. Suppressor cells are readily generated when 
either antigen is administered in a form inimical to macrophage 
uptake, or when antigen is present in excess. In contrast, an immune 
response is seen if insoluble complexes of antigen, such as would 
occur due to macromolecular complex formation between polyanion and 
polycations, are administered. The presence of adjuvants which 
’•activate" macrophages further enhances the immune response (Saito 
and Gefter, 1981).
3.5 Immunosuppressive influence of carrageenan
Carrageenans are being widely used as modifiers of the immune 
response in various animals particularly mice (Rumjanek and Brent,
1978; Turner and Higginbotham, 1977; Thomson, 1978; Thomson, Fowler 
and Pugh-Humphreys, 1979; Fowler and Thomson, 1979; Sakemi, Kuroswa 
and Nomata, 1980; Kolb ert al. , 1981; Thomson et_ al^ . , 1981). Carrageenans 
have been reported to be toxic to macrophages in vitro (Allison, 
Harrington and Birbeck, 1966; Yung and Cadkowicz, 1978), and in vivo 
(Gordon, MacIntyre and McMillan, 1977; Simon and Jones, 1979; Lee,
1981).
A macrophage population is required for non-self detection in, 
for instance, bone marrow transplants in irradiated animals. Studies 
on the influence of the three fractions of carrageenan indicated that 
carrageenan suppressed resistance to grafts when a carrageenan dose 
of 500 |ig per irradiated mouse was injected intravenously several 
hours before or after transplantation (Yung and Cudkowicz, 1977). The 
authors found that X- and i-carrageenan were more effective than 
K-carrageenan, and that suppression was enhanced when irradiation
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preceded transplantation by 24 hours.
Although the detailed mechanism of carrageenan-induced toxicity 
of macrophages is still to be elucidated, carrageenan is known to be 
readily taken up by macrophages, causing swelling and rupture of cells 
and apparently resulting in cell death since macrophages cannot 
readily degrade carrageenan (Ishizaka _crt al. , 1980) .
Carrageenans have been shown to act on lymphocytes, especially 
B cells, resulting in polyclonal antibody production, although previous 
studies suggested that carrageenans act only on macrophages and not 
on lymphocytes (Ishizaka e^t al^ . , 1980; Cateinzaro, Schwartz and 
Graham, 1971). These differences may simply be due to different types 
of carrageenan having different biological activities.
Macrophage activity in the induction of inflammation is well 
documented and A-carrageenan was shown to have the greatest inflammatory 
activity (Davies and Allison, 1976) . Other work (Ishizaka et al_. ,
1980) indicated, however, that there was no difference in polyclonal 
antibody production elicited by the three different carrageenan 
fractions assayed.
Carrageenans have been used together with other immunosuppressive 
drugs to prolong renal allograft survival in dogs (Caine, Wall and 
Wilkins, 1975). A-Carrageenan was similarly found to be the most 
immunosuppressive of the fractions when given to rats which received 
heart transplants (Everson, Stacey and Bell, 1977). These effects 
were thought to be mediated through macrophage toxicity induced by 
the carrageenan. Mortality in these rats was high. However, the 
remaining rats had a high transplant survival time. Mortality may 
have been due to many factors such as bleeding from the operation site,
disseminated intravascular coagulation and diverse effects of carrageenan 
on the blood.
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4. THE RODENT SYSTEM
4.1 The rat
Within this study the rat was chosen as the experimental model 
to investigate Factor Xll-related responses including coagulation, 
fibrinolysis and inflammation. The activation of the early stages of 
blood coagulation per se not only involve the above interrelated 
pathways but result in stimulation of platelet responses which have 
profound effects on blood flow. Similarly,the dissolution of a 
blood clot through the action of the enzyme plasmin yielding fibrinogen 
degradation products which are known to participate in immune responses 
(Girman et al., 1976).
The rat model has been widely used in the study of allograft 
rejection (Everson, Stacey and Bell, 1977), inflammation (Schwartz 
and Kellermeyer, 1969) and immune responsiveness (Wilson et al,, 1978). 
Consequently this model affords both ex vivo and in vitro testing 
facilities with which the Factor Xll-related pathways may be explored 
and perturbed using animal groups yielding statistically significant 
results both per animal and for total group size. In conclusion?the 
rodent system offers an ideal opportunity through which these complex 
pathways may be overviewed in an attempt to gain an understanding of 
the physiological effects of carrageenan on these test systems.
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Objectives of the study
The objectives of this thesis may be defined under the following:-
1. To study the effect of carrageenan on Factor Xll-mediated responses. 
In particular,the interaction of these polyelectrolytes with:
a) Factor Xll-mediated blood coagulation;
b) Factor Xll-dependent fibrinolytic activity;
c) Factor Xll-prekallikrein activity.
The above responses are to be monitored using both amidolytic 
and functional techniques.
2. To investigate carrageenan-platelet effects and their possible role 
in vitro and ex vivo with respect to the responses outlined above.
3. Lipoproteins have been directly related to the onset of athero­
sclerosis and as such a study of carrageenan effects on lipoproteins, 
separated by density centrifugation, was carried out ex vivo.
4. Carrageenans have been noted to be immunosuppressive. The production 
of fibrinogen degradation products have also been found to modify 
immune responses. Consequently,any Factor Xll-mediated response
as generated or inhibited by carrageenan may directly affect 
immune reactions.
In summary, to the author’s knowledge an integrated study of in vitro 
and ex vivo carrageenan effects using a single rat model has not been 
undertaken.
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Ill MATERIALS AND METHODS
Polysaccharides
Carrageenans
Carrageenas were a gift from Mr. J. Pederson, Pectin Factory, 
Copenhagen, Denmark, and chemical analyses are detailed (Table 1, 
p. 50).
Infra-red analysis was carried out for each polysaccharide by 
J. Pederson and the spectra for the 1- and K-carrageenans were 
found to be typical for these types of polysaccharide (J. Pederson, 
personal communication). The X-carrageenan isolation process involved 
full alkali modification (J. Peterson, personal communication) as 
the spectra on page 48a illustrates (Rees, 1963; Percival, 1972). 
Subsequently this carrageenan will be referred to as alkali-modified 
X-carrageenan throughout the text.
The salt forms of carrageenan used in this study reflect the 
method of isolation and purification as stated by the manufacturer.
Lyophilised samples were reconstituted in saline at a concentration 
of 10 mg ml pH 7.4. To aid dispersion the samples were heated in 
a 60°C water bath for 5 minutes. Prior to addition to plasma or 
injection, samples were further dispersed by vortexing for 30 seconds.
Glycosaminoglycan
Heparin (Porcine intestinal mucosa, grade 1, Lot No. 46C-0035) 
was obtained from Sigma Chemical Company Ltd., Poole, Dorset, U.K.
The sodium salt form of heparin was found to contain 31.2% sulphate 
(w/w) ester.
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Heparin was dissolved in saline, pH 7.4 at a concentration 
of 10 mg ml 1.
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TABLE 1
Chemical analysis of lambda, iota and kappa carrageenans
Carrageenan Salt Form No. Sulphate
%*.
Calcium
%*
Potassium
%*
Sodium
%*
Lambda (X) Potassium 022100 29.94 0.29 10.04 0.14
Iota (1) Sodium 32460 32.10 0.47 5.75 2.34
Calcium 32510 34.2 1.74 5.58 1.46
Kappa (K) Calcium 52731 22.9 0.85 5.25 0.65
Potassium 52405 22.0 0.28 7.02 0.55
♦Calculated on a weight to weight basis
Preparation of buffers and general reagents
Acetate buffer pH 4.0 
Sodium acetate
pH adjusted to 4.0 with 1M acetic acid
Acetate buffer pH 5.7 
Sodium acetate
pH adjusted to 5.7 with 1M acetic acid
Phosphate buffer pH 7.4
Trisodium orthophosphate 
pH adjusted to 7.4 with 1M HC1
Phosphate-buffered saline pH 7.2
Monobasic sodium phosphate 
Dibasic sodium phosphate 
Sodium chloride 
Sodium azide
pH adjusted to 7.2 with 1M HC1
Tris (hydroxymethyl) methyl amine-HCl buffer pH 8.0
Tris (hydroxymethyl) methyl amine 
HC1
To Tris (50 mis) add HC1 (26.8 ml) then make up to 
200 ml with distilled water 
pH adjusted to 8.0 with 1M NaOH
0.06M
0.015M
0.1M
0.036M
0.065M
0.150M
0.0015M
0.1M
0.1M
51.
Tris (hydroxymethyl) methyl amine-HCl buffer pH 7.8
Tris (hydroxymethyl) methyl amine
Sodium chloride
pH adjusted to 7.8 with 1M HC1
Carbonate-bicarbonate buffer pH 9.6
Sodium carbonate 
Sodium bicarbonate 
Sodium azide
pH adjusted to 9.6 with 1M NaOH 
Veronal-buffered saline - Triton X 100
One veronal buffer saline tablet (Sigma per) 100 ml water 
Triton X 100
Glycine-hydroxide buffer pH 10.4
Glycine (50 mis)
Sodium hydroxide (38.6 mis)
Magnesium chloride 
Zinc chloride
Made up to a final volume of 200 mis with distilled water 
pH adjusted to 10.4 with 1M NaOH
Cholesterol acid reagent
Glacial acetic acid
Acetic anhydride (concentrated)
0.012M
0.05M
0.02M
0.027M
0.0015M
0.01% w/v
0.2M
0.2M
0.001M
0.001M
200 mis 
210 mis
Sulphuric acid (concentrated) 30 mis
Ethanolic potassium hydroxide
Potassium hydroxide in absolute ethanol 0.35M
Sodium hydroxide in water pH 12.8 1 .5M
Calcium chloride dihydrate in distilled water pH 7.4 0.25M
Saline pH 7.4
Sodium chloride in distilled water 0.15M
Anticoagulant solution pH 7.4
Trisodium citrate dihydrate in distilled water 3.8% w/v
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General Reagents
Adenosine 5-diphosphate, e-aminocaproic acid, Polybrene, 
(hexadimethrine bromide), flufenamic acid, Russell's viper venom, 
rat Immunoglobulin G, anti-rat Immunoglobulin G, 104 phosphate 
substrate, gluteraldehyde, alkaline phosphatase (Type VIIs),
Cephotest and Tris-Trisma base were obtained from Sigma Chemical 
Company Ltd., Poole, Dorset, U.K.
Bovine topical thrombin (Batch No. AC657) was obtained from 
Parke-Davis and Company, Detroit, Michigan, U.S.A. The lyophilised 
material was dissolved in the diluent provided, then further diluted 
to a concentration of 100 NIH U ml ^ with saline. Samples were 
stored in sealed plastic tubes at -20°C until required, then diluted 
to the required strength with saline and kept on ice and used within 
1 hour.
Human fibrinogen was obtained from KabiVitrum, Ealing, London,
U.K. Fibrinogen was reconstituted with distilled water to give lOg
-1 o1 and stored in aliquots (2 ml) in sealed plastic tubes at 20 C
until required.
Amidolytic substrates were obtained from Flow Laboratories, 
Irvine, Ayrshire, U.K. Amidolytic substrates: Bz-Ile-Glu-Gly-Arg-
pNA (S-2222) and H-D-Pro-Phe-Arg-pNA (S-2302) were dissolved in 
distilled water at a concentration of 4 mM and stored in a dark 
bottle at 4°C. Amidolytic substrate H-D-Phe-Pip-Arg-pNA (S-2238) 
was dissolved in distilled water to give a concentration of 0.75 mM 
and stored as above. Amidolytic substrate H-D-Val-Lau-Lys-pNA 
(S-2251) was dissolved in distilled water to a concentration of 1.0 mM 
and stored as above.
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Platelin (rabbit brain phospholipid) was obtained from General
Diagnostics, Warner Bros., Eastleigh, Hants., U.K. The lyophilised 
reagent was dissolved in distilled water as directed by the manu­
facturer, then further diluted 1:2 with saline and kept on ice 
until required.
Heparin-Sepharose 4B was obtained from Pharmacia Fine Chemicals, 
Hounslow, Middlesex, U.K. The gel (5g) was swollen and equilibrated 
using phosphate buffer (0.1M, pH 7.4).
Polystrene beads (3.2 mm diameter) were obtained from Euromatic 
Ltd., Brentford, Middlesex, U.K.
Sheep red blood cells and Minimal Essential Media were obtained 
from Gibco Ltd., Paisley, U.K.
Antisera specific for rat or mouse: IgG and IgM were purchased 
from Miles Laboratories, Stoke Poges, Slough, U.K.
oStock solutions of thrombin and fibrinogen stored at -20 C 
were routinely tested for clotting activity by coagulation assay 
tests on pooled control plasma.
All other reagents used were obtained from Sigma Chemicals 
Ltd., Poole, Dorset, U.K. and were of Analar grade unless otherwise 
stated.
Methods
Route of polysaccharide administration
Solutions of carrageenans (10 mg ml *) were prepared in saline 
and injected into the intraperitoneal cavity,according to rat weight, 
using a graduated polypropylene syringe (1.0 ml) and 20 x l£g needle.
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In order to determine a zero hour response the animal was bled 
immediately, under anaesthetic, by cardiac puncture. For subsequent 
sampling the rat was allowed to recover before being returned to a 
cage, then subsequently anaesthetised and bled by cardiac puncture. 
Repeated anaesthesia was found to have no significant effects on 
the experimental results.
Treatment of experimental results
Results obtained were expressed as the mean and standard error 
where the number of readings (n) was no less than three for in vitro 
studies and n> 5 for ex vivo studies. In some cases standard error 
bars lay within the dimensions of the symbol.
For each assay the control values were obtained and are presented 
together with the number of readings per point. Where clotting time 
exceeded the control value by an arbitory factor of 5,a clotting time 
of infinity (°°) was recorded. Activities in ex vivo assays were 
expressed in relation to similar activities recorded in control 
saline-treated animals used over the same time course as the test 
animals.
Preparation of plasma 
Platelet-rich plasma
Rats were anaesthetised, then bled by cardiac puncture into a 
polypropylene syringe (10 ml) containing 3.8% w/v trisodium citrate (9 
volumes of blood to 1 volume citrate) using a 20g x l£ gauge needle. 
Whole citrated blood was centrifuged at 200 x g for 10 minutes 
at ambient temperature (25°C). The red cell-free platelet suspension 
was transferred to a plastic tube and used immediately. Pooled plasma
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was obtained from not less than 4 animals. Microscopic analysis was 
carried out to confirm that a red cell free preparation was obtained.
Platelet-poor plasma
Following removal of platelet-rich plasma, the remaining blood 
was further clarified by centrifugation at 750 x g for 10 minutes at 
ambient temperature. The supernatant was transferred to a plastic 
tube and, unless stated, used immediately. A plasma pool from no 
less than 4 animals was used.
For ex vivo studies the animals were injected intraperitoneally 
with polysaccharide according to animal weight, then plasma prepared 
as above. Samples were kept separate in this instance and immediately 
assayed.
Preparation of modified plasma
The use of plasma depleted of proteinases or proteinase inhibitors 
allowed comparison of polysaccharide-protein interaction in the 
presence and absence of proteins associated with the coagulation 
pathway.
Factor Xll-depleted plasma
The depletion of Factor XII from normal pooled rat plasma was
carried out using the method of Nossel (1966). To pooled rat plasma
(4 ml) in a polyethylene tube was added Whatman Celite 512 (20 mg
ml "S . The tube was sealed and incubated at 37°C for 70 minutes,
with frequent mixing of the contents during the course of the incubation.
oThe preparation was centrifuged at 2,500 x g for 10 minutes at 4 C.
The supernatant was removed and dispensed into a plastic tube and
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omaintained at 37 C for 18 hours prior to use.
Thrombin clotting time, Russell1s viper venom clotting time 
and partial thromboplastin clotting time were carried out on plasma 
sample both in the presence and absence of polysaccharide.
Antithrombin Ill-depleted plasma
Antithrombin III (AT III) was depleted from normal rat plasma 
by the method of Barrowcliffe et^  al. (1978). Plasma was eluted 
through a column containing Heparin-Sepharose 4B by the following 
procedure.
To a 5g sample of freeze-dried Heparin-Sepharose 4B (Pharmacia 
Chemicals) was added phosphate buffer (0.1 M pH 7.4) in a glass 
filter; the Heparin-Sepharose was then washed with the buffer 
(150 ml). The gel (30 ml) was packed into a plastic column (Pharmacia 
Chemicals) and equilibrated with 20 washes of phosphate buffer 
(0.1 M pH 7.4) until the absorbance of the eluant at 280 nm fell 
below 0.05. All procedures were carried out at 4°C.
Excess plasma was applied to the column at a flow rate of 1.0 
ml minute \  Once plasma started to elute, it was continuously 
passed through the column for three hours. The AT III plasma was 
then collected in plastic tubes and used immediately. AT III was 
eluted from the column using a sodium chloride gradient of 0-1.5M 
in phosphate buffer (0.1M pH 7.4).
Preparation of serum
Rats were anaethetised and bled by cardiac puncture into a 
polypropylene syringe (10 ml ) using a 20g x l£ gauge needle. The 
uncitrated blood was transferred to glass tubes and left at room
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temperature for 2 hours to allow clot retraction. The clot formed 
was removed and the supernatant centrifuged at 750 x g for 5 minutes. 
The resultant cell-free serum was used immediately.
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1 COAGULATION STUDIES
1.1 Clotting assays
Standard procedures for clotting were used in the study of 
carrageenan effects on the intrinsic pathway of blood coagulation.
The galactan sulphate effects on whole blood, Factor XII, Factor X 
and thrombin clotting time were investigated. Carrageenan effects 
on plasma systems both in the presence and absence of proteinases 
and their inhibitors were examined in order to elucidate potential 
interactions of macroions. Amidolytic assays were used,where appropriate, 
in support of the functional clotting technique to further highlight 
points of interaction in the coagulation cascade.
1.1.1 Whole blood clotting assay
The method was modified from that of Lee and White (1913) 
and carried out in a plastic test system. Carrageenan was prepared 
in saline to give a final concentration of 1.0 mg ml * and further 
dilutions were carried out in saline.
Whole citrated blood was obtained from non-treated animals.
Saline or carrageenan (100 yl) was added to whole citrated blood 
(200 yl) in plastic tubes. Mixing was ensured by vortex mixing 
for 15 seconds before placing the tubes in a water bath (37°C).
Calcium chloride (0.025M; 100 yl) was added and mixed by vortex 
for 15 seconds. The tubes were incubated in the water bath and 
tilted through an 180° angle every minute until a clot was observed.
The time taken for each clot to form was noted and the arithmetic 
mean of triplicate experiments was obtained.
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The coagulation cascade is known to be activated when the blood 
(plasma) comes into contact with negatively charged surfaces such as 
glass or kaolin. Such surfaces were avoided in the following procedure 
so that the effects of polysaccharides themselves could be ascertained.
If no clot formed in the tube containing polysaccharide after 
1000 seconds,a clotting time of greater than 1000 seconds was recorded.
1.1.2 Partial thromboplastin clotting time assay
The method used was a modified form of the method of Langdell 
and Wagner (1955) using a plastic system and an automatic coagulometer.
Normal rat platelet-poor plasma from four male rats was obtained 
and pooled. Carrageenans and heparin were dissolved to a concentra­
tion of 1.0 mg ml * in saline and diluted further in saline. Platelin 
was prepared according to the instructions given by the manufacturer 
then further diluted 1:2 with saline.
Carrageenan, heparin or saline(100 yl) was added to plasma (100 yl) 
in a plastic tube. The mixture was incubated at 37°C for 120 seconds 
prior to the addition of platelin. After 60 seconds incubation, 
calcium chloride (0.025M, 100 yl) was added and the automatic timer 
started. The clotting time was taken as the mean of triplicate 
readings.
If a clot in the presence of polysaccharide had not formed after 
300 seconds, a clotting time of greater than 300 seconds was recorded. 
Control readings in the absence of carrageenan were in the range 
40-55 seconds.
The above method was also used in plasma samples depleted of 
Factor XII by celite exhaustion.
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For ex vivo assays, plasma was obtained from polysachharide-
injected animals. To plasma (100 yl) was added platelin (100 yl)
oand the solution mixed and incubated for 60 seconds at 37 C before 
the addition of calcium chloride (0.025M, 100 yl).
Triplicate readings were obtained per animal with no less 
than five animals per group.
1.1.3 Russell’s viper venom clotting assay
A modification of the method of Furie £t aT (1974) was used to
study the effects of polysaccharides on Factor X activation. Plasma
from six male rats was pooled. Russell’s viper venom was dissolved
-4 -1in saline to give 1 x 10 g ml and mixed 1:16 (v/v) with platelin 
(Platelin/RVV).
Plasma (100 yl) in plastic tubes was incubated with polysaccha­
ride or saline (100 yl) for 120 seconds at 37°C. Platelin/RVV (100 
yl) was added and mixed, then incubated at 37°C for 30 seconds. 
Calcium chloride (0.025M, 100 yl) was added and the clotting time 
recorded. The mean of triplicate readings was recorded. A reading 
of greater than 300 seconds was recorded. This method was repeated 
for Factor Xll-depleted and AT Ill-depleted plasma.
For ex vivo studies, plasma was collected from animals which 
had previously been injected with polysaccharide and the assay 
carried out as detailed below.
To plasma (100 yl) was added Platelin/RW (100 yl) and the
omixture incubated at 37 C for 30 seconds prior to the addition of 
calcium chloride (0.025M, 100 yl). Triplicate readings per animal 
were recorded.
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1.1.4 Thrombin clotting time assay
Thrombin clotting time was assayed by a modification of the
method of Ratnoff (1954). Plasma (100 yl) was incubated with carra-
ogeenan (100 yl) in a plastic tube for 120 seconds at 37 C. Thrombin 
(25 NIH U ml 1, 100 yl) was added and the clotting time recorded.
The mean of triplicate readings was recorded.
This method was also carried out for Factor Xll-depleted and 
AT Ill-depleted plasma.
For ex vivo assays, plasma (100 yl) from injected animals was 
incubated with saline (100 yl) for 120 seconds prior to addition 
of thrombin (25 NIH U ml 1 , 100 yl). The average of triplicate 
readings per animal was recorded.
1.2 Amidolytic assays
1.2.1 Determination of Factor X in plasma
Factor X activity in rat plasma was determined using the method 
of Aurell jet j Q . (1977) .
Plasma was diluted 1:25 (v/v) with Tris-NaCl buffer pH 8.0
(Tris 0.05M; NaCl 0.227M). Polysaccharide (1.0 mg - 1.0 yg ml *),
heparin (1.0 mg - 1.0 g ml "S or saline (50 yl) was added to the
diluted plasma (200 yl) and incubated for 180 seconds prior to the
addition of 50 yl of a 2:1 (v/v) mixture of Russell's viper venom
(0.1 mg ml *) and calcium chloride (0.4M). The solution was incubated
ofor a further 60 seconds at 37 C before addition of substrate S2222 
(0.008M; 200 yl). Acetic acid (50% v/v; 300 yl) was added after 
15 minutes to stop further reaction. Interaction of the enzyme with 
the chromogenic substrate resulted in the release of a chromophore
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paranitroanaline, the absorbance at 405 nm of which was measured 
spectrophometrically.
Ex vivo assays were carried out using plasma obtained from 
polysaccharide-injected animals. To diluted plasma (200 yl) 
was added Russell's viper venom and calcium chloride as above. After 
incubation for 60 seconds at 37°C, substrate was added and the re­
action terminated after 15 minutes by addition of acetic acid (300 
yl). Spectrophotometric readings were obtained as detailed above.
1.2.2 Determination of thrombin activity in plasma
Thrombin activity was assayed by the method of 0degard (1975).
Plasma was diluted 1:61 (v/v) with Tris buffer (0.05M) pH 8.4 
containing disodium ethylene diamine tetra acetic acid (0.0075M) 
and sodium chloride (0.175M).
To diluted plasma (200 yl), polysaccharide (1.0 mg - 1.0 yg ml "S , 
heparin (1.0 mg - 1.0 yg ml *) or saline (50 yl) was added and incubated 
for 180 seconds prior to the addition of thrombin (10 NIH U ml 
50 yl). Following incubation for 30 seconds, a mixture containing 
substrate S2251 (0.5M) and Polybrene (0.34 mg ml 1) was added (150 yl) 
and incubation continued for 30 seconds. The reaction was stopped by 
the addition of acetic acid (50%, 300 yl).
The ex vivo assays were carried out using plasma from injected 
animals. To diluted plasma (200 yl), thrombin was added (50 yl); 
then the mixture was incubated for 30 seconds prior to the addition 
of the substrate-Polybrene mixture (150 yl). Amidolysis was stopped 
after 30 seconds by the addition of acetic acid (300 yl) and the 
samples assayed as detailed previously.
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2. FIBRINOLYSIS
Enzymic cleavage of Factor XII not only results in the initiation 
of the coagulation cascade but also activation of the fibrinolytic 
and kallikrein pathways. The fibrinolytic and kallikrein systems 
were studied to further investigate the possible sites of poly­
saccharide-plasma proteinase.
2.1 Euglobulin precipitation of plasma
Preparation of the euglobulin fraction of plasma was performed 
using a modification of the method of Kluft, Brakman and Veldhuyzen- 
Stolk (1976).
To a polycarbonate tube was added plasma (1.0 ml) and polysaccha­
ride (1 mg - 1 yg ml "S or saline. The preparations were mixed and 
incubated at 37°C for 10 minutes prior to the addition of glacial 
acetic acid (0.017% v/v; 9 ml). The tubes were sealed, and then 
the contents were thoroughly mixed and maintained at 4°C for 2 hours. 
The tubes were centrifuged at 750 x g for 10 minutes at 4°C and 
the supernatant discarded. The tubes were inverted and, in order 
to remove residual supernatant, dried with a cone of filter paper 
(Whatman No. 1). The euglobulin pellet was resuspended in Tris HC1 
buffer pH 7.8 (1.0 ml).
2.2 Inhibition studies
The mechanism of carrageenan-induced fibrinolytic activity 
was investigated by experiments designed to study plasminogen- 
plasmin induced fibrinolysis. Initially e-ACA (2 mM), a plasmin­
ogen inhibitor was added to plasma and incubated for 3 minutes
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oat 37 C prior to euglobulin precipitation. Secondly, flufenamic 
acid (12 mM), an inhibitor of plasmin production via an influence 
on an inhibitor of the first component of the complement pathway, 
was incorporated into the plasma and treated as above.
Ex vivo studies involved the use of plasma from polysaccharide- 
injected animals, and the incorporation of saline, e-ACA or 
flufenamic acid prior to euglobulin precipitation.
2.3 Preparation of fibrin plates
Stock fibrinogen (10 g 1 1) was prepared in distilled water
oand stored in plastic tubes at -20 C. Thrombin was prepared at a 
concentration of 100 NIH U ml 1 and similarly stored at -20°C.
Petri dishes were marked into quadrants, and a filter paper 
attached to the inner surface of the lid. The paper was moistened 
in order to prevent drying of the plate.
Stock fibrinogen was further diluted with Tris HC1 pH 7.8
and aliquots (2 ml) were put into plastic tubes along with Tris
HC1 buffer pH 7.8 (7 - 8 mis). Thrombin (10 NIH U ml"1, 200 \il)
was added and the tube inverted, care being taken to avoid the formation
of bubbles. The resultant solution was carefully poured in the Petri
dish, care again being taken to avoid the formation of bubbles, and
the contents allowed to set evenly in the dish. Plates were then
left at 37°C for one hour, and euglobulin test solutions (30 yl)
were added to plates within two hours of preparation. The plates
were incubated at 37°C for 18 hours after which they were inspected
for areas of lysis. The area of lysis was calculated as the product
2of two perpendicular axes with the results expressed in mm . The 
mean and standard errors of duplicate readings were then presented 
graphically.
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3. KININ SYSTEM
3.1 Determination of prekallikrein in plasma
Prekallikrein activation in rat plasma was measured by the 
method by Claesson et al. (1978). Plasma was diluted 1:12 (v/v) 
with Tris buffer (0.05M) pH 7.8 containing sodium chloride (0.012M).
Cephotest, diluted 1:10 (v/v) with buffer pH 7.8 was used as 
an activator. In a plastic tube Cephotest (400 yl) was added to
diluted plasma. The mixture was then incubated for 180 seconds with
-1 -1 polysaccharide (1.0 mg - 1.0 yg ml ), heparin (1.0 mg - 1.0 yg ml )
or saline (50 yl). Following incubation for 120 seconds,substrate
S2302 (4 mM) was added (100 yl) and the mixture further incubated
for 60 seconds. The reaction was stopped by the addition of acetic
acid (50% v/v, 300 yl).
In all assays, reagent concentrations quoted are final concentra­
tions in the reaction mix prior to acetic acid addition. Appropriate 
control tubes containing separately no polysaccharide, heparin, 
enzyme or substrate were included.
Paranitroaniline (pNA) released from substrates was determined 
spectrophotometrically at 405 nm using an SP 1800 spectrophotometer. 
Absorbance measured in control tubes was in the range 0.5 - 0.6.
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4. PLATELET STUDIES
4.1 Platelet studies using platelet-rich plasma
Platelet-rich plasma (PRP) was prepared as previously described.
A platelet count was determined by the addition of PRP (100 yl) to 
ammonium oxalate (1% w/v, 1900 yl). The mixture was allowed to stand 
for 20 minutes at ambient temperature before cells were counted with 
an improved Neubauer cell counting chamber and using phase contrast
microscopy. Cell counts were always adjusted to a range of 2.4 - 3.5
5 -3x 10 platelets mm
4.2 Platelet aggregation
Platelet aggregation studies were carried out using a modification 
of the method of Born (1962).
A single channel aggregometer (Malin Electronics, Ayr, U.K.) 
and a single channel recorder (Linseis GMBH, Germany) were used.
The aggregometer and recorder were calibrated with PRP (0% light 
transmission) and PPR (100% light transmission) as arbitary values 
for each plasma sample.
To PRP (140 yl) was added polysaccharide (1 mg - 1 yg ml 1) or 
saline (10 yl). The solution was stirred at 900 rpm at 37°C for 
3 minutes before the addition of thrombin (10 yl) or ADP (10 yl) 
and aggregation was observed. The test volume of the reaction mix 
within the cuvette was always 160 yl.
Ex vivo assays for platelet aggregation involved plasma (140 yl) 
from polysaccharide-injected animals. The plasma was treated with 
ADP (50, 10, 1.0 mM; 10 yl) and thrombin (1.5, 1.0, 0.5 NIH U ml”1 ,
10 yl).
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4.3 Platelet adhesiveness
Assays of platelet adhesiveness were performed using the 
method of Morris et al. (1978). To saline-washed glass beads 
(100 microns, 250 mg) was added platelet-rich plasma (250 yi) 
from carrageenan-treated animals. The tubes were rotated 
through 360° for 1 minute then left at ambient temperature for one 
hour to allow the beads to settle.
The supernatant (50 yi) was removed into a dye solution 
containing 1:1 (v/v) mix of 20% (w/v) urea (to lyse red cells) to 
1% bromqphenol blue (to stain platelets) (1.0 ml). A sample was 
then removed and transferred to a haemocytometer and the platelets 
counted.
Percentage adhesiveness was calculated as:
No. of platelets in control sample-No. of platelets in test sample 
No. of platelets in control sample x 100
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5. IMMUNOGLOBULIN STUDIES
5.1 Enzyme-linked immunosorbent assay for rat Immunoglobulin G
Animals were injected and serum samples collected as described 
previously (p. 58).
Preparation of crude globulin
Anti-rat IgG (sheep) was precipitated from solution with 
2 volumes of disodium sulphate (27% w/v) and the mixture left at room 
temperature for 15 minutes. The mixture was centrifuged at 1200 x g 
for 10 minutes and the precipitate obtained resuspended in saline 
(2 ml ). In order to remove excess sulphate the suspension was 
dialysed against buffered saline (PBS) for 12 hours at 4°C.
Estimation of protein concentration
The protein content of the globulin was determined spectrophoto- 
metrically at 280 nm.
Conjugation of alkaline phosphatase
Conjugation was carried out as outlined by Parratt, Nielson
and White (1977). Alkaline phosphatase was combined with anti-rat
IgG to a ratio of 3:1 (w/w). The alkaline phosphatase suspension
owas centrifuged (750 x g, 10 minutes, 4 C) and the supernatant 
discarded. The pellet was resuspended in the required volume of 
anti-rat IgG. The mixture was then dialysed against PBS pH 7.4 
for 48 hours with two changes of PBS. Following dialysis, the mixture 
was transferred to a plastic tube and the volume made up to 
1.25 ml with PBS.
Gluteraldehyde required for optimal conjugation of enzyme and 
antibody was added to a final concentration of 0.2% v/v. The mixture
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was left at ambient temperature for 2-4 hours until a pale yellow 
colour developed. Finally, the solution was dialysed against 3 
changes of PBS pH 7.4 (2 1) and one change of Tris buffer (0.05M, 
pH 8,2 1) containing magnesium chloride (0.001M). The buffer was 
changed every 24 hours. The resultant solution was stored in a 
plastic tube at 4°C.
Coating the plastic beads
Polystyrene beads (2.2 mm) were thoroughly washed with 
distilled water. Each bead required 0.05 ml carbonate bicarbonate 
buffer pH 9.6. IgGwas dissolved in buffer at a concentration of 100 yg 
ml The beads were added to the beaker containing the anti-rat 
IgG and buffer, sealed and incubated for 3 hours at 37°C, and then 
kept at 4°C until required.
Preparation of standard rat Immunoglobulin G
Rat IgG (10 mg) was resuspended in saline to give a final 
concentration of 5 mg ml Dilutions were carried out in veronal- 
buffered saline (VBS) containing Triton X 100 (0.01% v/v) prior to 
use.
Assay for rat Immunoglobulin G
Standard rat IgG dilutions were prepared together with 
dilution (1:4000) of serum from carrageenan-treated and control 
animals.
To plastic tubes, a single coated bead was added and washed 
(x3) in VBS-Triton X 100 buffer (500 yl). Samples of diluted sera 
were transferred to tubes (250 yl) and left at ambient temperature 
for 30 minutes. Excess protein was washed off (x3) with VBS-Triton X 
100 (500 yl). Conjugate was prepared by dilution (1:100) with VBS-
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Triton X 100 and added to each tube (250 yl). Tubes were left at 
ambient temperature for 30 minutes and then washed (x3) with VBS- 
Triton X 100 (500 yl).
Substrate was prepared by dissolving one 104 phosphatase sub­
strate tablet in glycine-hydroxide buffer (5 ml) , then added to 
each tube (250 yl) and left at ambient temperature for 6 minutes 
prior to the addition of sodium hydroxide solution (1.5M: 600 yl) 
to terminate the reaction.
Absorbance of each sample was measured at 405 nm using an SP 
1800 spectrophotometer and the protein concentration for each sample 
obtained from a calibration curve set up using pure IgG.
5.2 Haemagglutination assay
This assay was carried out using the method of Herbert (1967) 
to determine antibody formation in rat serum.
Rats were injected through the peritoneal cavity with 20 mg
-1 9 -1kg polysaccharide,followed 24 hours later by 2.5 x 10 cells kg ,
by the same route, of sheep red blood cells in saline.
The concentration of rat antibody for IgG is greatest at 8 days 
after antigen addition and so at this time the animals were bled by 
cardiac puncture and serum obtained.
The collected serum was complement-inactivated by immersion in a 
56°C water bath for 30 minutes. Ovalbumin (0.1% w/v, 25 yl) was 
added to wells (1-12) of microtitre plates and to well 1 serum (25 yl) 
was added. The serum was serially diluted with a multichannel mixer.
9 - 1Sheep red blood cells (1 x 10 cells ml , 25 yl) were added
oto each well and the well contents mixed and then incubated at 37 C
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for 45 minutes. The titration end point was taken as the last well
to show visible agglutination. Readings were taken as the inverse 
of the dilution factor, means obtained and the results expressed as 
the ratio of polysaccharide injected rat serum to saline rat serum.
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6. LIPOPROTEIN STUDIES
6.1 Determination of serum cholesterol
Serum separation into its component lipoprotein fractions was 
carried out by a modified method of Hatch and Lees (1968).
Standard solutions with known densities were prepared with KBr 
oat 20 C and measured by pyknometry. The following calculations were 
employed in the preparation of the solutions:
Volume of fluid (required density - initial density) 
Required density = 1-specific density of KBr (required density)
The solutions were prepared as seen in Table 6.1.1 and solutions of 
densities 1.045 g ml 1 and 1.15 g ml * were prepared using the above 
equation.
6.2 Lipoprotein separation
In an ultracentrifuge tube, serum (5 ml) was added to a 1.008 g ml * 
solution (1.0 ml) and mixed. The tubes were carefully balanced (<0.001 g 
difference) and centrifuged at 108,000 x g for 16 hours at 14°C. The 
very low density lipoproteins (VLDL) were pipetted off, using the 
technique of deLalla, Elliott and Goffman (1954), to a marked 4 ml 
level. The VLDL was transferred to a 5 ml volumetric flask and made 
up to 5 ml with 1.008 g ml 1 solution.
The remaining lipoprotein were thoroughly mixed with a solution of 
density 1.045 g ml 1 (2 ml) and centrifuged at 108,000 x g for 16 hours 
at 14°C. The intermediate density lipoproteins (IDL) were removed 
as before and made up to 3 ml with 1.008 g ml * solution.
To the centrifuge tube a 1.15 g ml 1 solution (1 ml ) was added
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Preparation of solutions for lipoprotein fractionation
Table 6.1.1
- 1Density 1.008 g ml
Sodium chloride 11.40 g
Disodium EDTA 0 .10 g
Sodium hydroxide (IM) 1 .0 ml
A 1000 ml volumetric flask was filled to volume with
distilled water followed by the addition of 3 ml of
distilled water. Density was checked by pyknometry.
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and the tubes centrifuged for 18 hours at 160,000 x g at 14°C. The 
low density lipoproteins (LDL) were removed as before and made up to 
5 ml with 1.008 g ml 1 solution. The remaining high density lipo­
proteins (HDL) were similarly made up to 5 ml volume.
oAll samples except VLDL were frozen at -20 until required. 
Standards were prepared from a stock solution of 40 mg ml * cholesterol.
6 .3 Determination of serum fraction cholesterol
All samples and standards were assayed in duplicate. To each
sample (200 |il) in a centrifuge tube was added ethanolic potassium
ohydroxide. The samples were thoroughly mixed and incubated at 37 C
for 60 minutes. To each tube petroleum spirit was added (4 ml)
followed by distilled water (2 ml). Mixing was carried out for 30
oseconds per tube prior to centrifugation (400 x g, 10 minutes, 20 C).
A volume of petroleum layer was removed, the amount depending 
on the fraction. For serum, control serum and LDL, 2 ml of petro­
leum was transferred to clean glass tubes and for VLDL, IDL and HDL 
3 ml were similarly treated. All petroleum samples were dried under 
a stream of nitrogen.
Acid reagent comprising acetic acid: acetic anhydride: sulphuric
acid was prepared in ratio 1.1:1.0:0.15 v/v. 6 ml of reagent was
added to the tube and the tube contents mixed for 30 seconds before 
oplacing in a 25 C water bath for 30 minutes. Absorbance readings 
were obtained at 620 nm using an SP 1800 spectrophotometer and 
converted to ml per 100 ml * serum from the standard curve.
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IV RESULTS
A. In vitro studies
A.1 Blood clotting assays
A.1.1 Whole blood clotting time
Polysaccharides, with the exception of K-carrageenan, exerted 
anticoagulant effects in the whole blood clotting assay (Graph A.1.1.1 
p.78). Comparison of activity was determined on a weight basis with 
heparin showing anticoagulant activity (>20 min) at 0.005 rag ml 1. 
Comparable anticoagulant activity was found with alkali-modified A-,
1 - and i -carrageenans at 0.5, 0.5 and 1.0 mg ml  ^respectively.
A control value obtained from saline-treated plasma gave a clotting 
time of 4 minutes.
To examine the polysaccharide effects more closely the intrinsic 
pathway of coagulation was examined in a cell-free system.
A.1.2 Partial thromboplastin time Clotting assay
Heparin was found to be anticoagulant (>200 s ) at 0.005 mg ml \  
while concentrations of 0.01, 0.05 and 0.01 were required for alkali- 
modified A-, l0a“ and t^a-carrageenan respectively to produce a similar 
response (Graph A.1.2.1, p.79). K-Carrageenan exhibited little anti­
coagulant activity even at high concentrations. A control value of
45.2 ± 2.4 s was obtained with saline-treated plasma.
A.1.3 Partial thromboplastin time in Factor Xll-depleted plasma
Results illustrated on Graph A.1.3.1,p. 80 show that with a saline control
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Graph A .1.1.1
The effect of heparin and carrageenan on whole blood
clotting time
The effect of heparin (O), alkali-modified A-carrageenan (•), 
lNa-carrageenan (□)> lCa_carrageenan (■) , i£a-carrageenan (<£$ 
and Kg-carrageenan (A) on whole blood clotting time. Control 
time was 4 minutes when n=3.
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Graph A .1.2.1
The affect of heparin and carrageenan on the partial 
thromboplastin clotting time of plasma
Effect of heparin (O) alkali-modified A-carrageenan (#) , iNa-carrageen an (□) 
lCa~carrageenan (□) , «Ca“ carrageenan and Kg-carrageenan 
on the PTT clotting time of plasma. Control time was 45.2 ±
2.4 s when n=3.
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Graph A .1.3.1
The effect of heparin and carrageenan on the partial thromboplastin 
clotting time of Factor XII depleted plasma
Effect of heparin (O), alkali-modified A-carrageenan (•), i - 
carrageenan (O) , i^-carrageenan (■) , K -carrageenan (<£*) and 
K -carrageenan (A) on the PTT clotting time Factor XII depleted 
plasma. Control time was 74.3 ± 0.7 s when n=3.
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value of 74.3 ± 0.7 s , heparin and the carrageenans exhibited an anti­
coagulant effect (>400 s'). Heparin and alkali-modified A-carrageenan 
required concentrations of 0.005 and 0.05 mg ml * respectively, while 
concentrations of 0 .1 and 1 .0 mg ml 1 were required by the 1-carrageenans 
and K-carrageenans to produce a similar response. The clotting time 
of Factor Xll-depleted plasma in the presence of saline was 74.3 s
A.1.4 Russell’s viper venom clotting time
A control value of 15.3 ± 0.1 s was recorded for this assay. 
Anticoagulant activity (>100 s ) was observed with all polysaccharides 
except the K-carrageenans. Concentrations of 0.01 and 0.5 mg ml  ^
were required by heparin and t -carrageenan respectively to produce an 
anticoagulant effect while 1 .0 mg ml 1 was required by alkali-modified 
A-carrageenan to produce a similar response (Graph A.1.4.1, p.82).
A. 1.5 Russell’s viper venom clotting time in Factor XII depleted plasma
Results obtained for this assay were similar to those recorded for 
normal plasma with a slight shift in concentration requirements for 
heparin from 0.01 mg ml 1 to 0.05 mg ml 1. The alkali-modified A- 
and l -carrageenan were found to be anticoagulant (>100 s ) atv a -1 -1 concentrations of 0.5 mg ml while l^-carrageenan required 1 .0  mg ml
for a similar response (Graph A.1.5.1, p.83). K-Carrageenans exhibited
no effect. Control values were found to be 14.5 ± 0.4 s
A.1.6 Russell’s viper venom clotting time in antithrombin Ill- 
depleted plasma
In AT Ill-depleted plasma, heparin anticoagulant activity was 
greatly reduced, even at high concentrations. With a control value of
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Graph A.1.4.1
The effect of heparin and carrageenan on Russell’s
viper venom clotting time of plasma
Effect of heparin (O), alkali-modified X-carrageenan (•) , -
carrageenan (□) , l ^ -carrageenan (■) , K^-carrageen an ani
K -carrageenan "on RVV clotting time of plasma. Control 
time was 15.3 ± 0.1 s when n=3.
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Graph A .1.5.1
The effect of heparin and carrageenan on Russell’s 
viper venom clotting time on Factor XII 
depleted plasma
Effect of heparin (O), alkali-modified X-carrageenan (#), 
carrageenan (□) , l ^ -carrageenan (■), « -carrageenan <£s) 
K -carrageenan on the RVV clotting time on Factor XII 
plasma. Control time was 14.5 ± 0.4 s when n=3.
lNa“and
depleted
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37.4 ± 2 .6 l l -andalkali-modified X-carrageenan were foundria La
to be anticoagulant (>100 s ) at 0.1, 0.5 and 1.0 mg ml * respect­
ively. As before, treatment of plasma with K-carrageenan did not 
affect the coagulant activity (Graph A.1.6.1, p.85).
A.1.7 Thrombin clotting time assay
All polysaccharides exerted an anticoagulant effect (>100 s ).
The concentrations required to obtain an anticoagulant effect for 
heparin and l -carrageenan were 0.005 and 0.01 mg ml 1 respectively.W &
Both alkali-modified X- and 1 -carrageenan required a concentration
of 0.05 mg ml while the K-carrageenans showed an anticoagulant 
effect at 0.5 mg ml 1 (Graph A.1.7.1, p.86). Control values were
22.2  ± 1 .0 s .
A.1.8 Thrombin clotting time in antithrombin Ill-depleted plasma
Heparin anticoagulant activity (>200 s ) was completely suppressed
in the absence of AT III while, in the absence of AT III, all carrageenans
- 1remained anticoagulant at concentrations of 0.5 mg ml or above (Graph 
A.1.8.1, p.87). With control values of 50.0 s ± 4.5 in this test 
system, procoagulant effects were observed with alkali-modified X-,
1 and K -carrageenan at 0.001 mg ml * and with Kp - and t -carrageenan 
at 0.05 mg ml * and below.
A.1.9 Factor X (Factor Xa)-catalysed amidolytic assay
Results expressed in Graph A.1.9.1, p. 88 illustrate that only
heparin inhibited the amidolytic activity of Factor X (Factor Xa),
an effect which occurred maximally between 0.05 - 0.1 mg ml Slight
inhibition was observed with K-carrageenan at 0.05 mg ml * but allK
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Graph A.1.6.1
The effect of heparin and carrageenan on Russell*s 
viper venom clotting time in plasma 
depleted of antithrombin III
Effect of heparin (O), alkali-modified A-carrageenan (<•) , tN - 
carrageenan (□), l^-carrageenan (■) , icCa-carrageenan anct
K^-carrageenan (A) on RVV clotting time of AT III depleted plasma 
Control time was 37.4 ± 2.6 s when n=3.
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Graph A.1.7.1
The effect of heparin and carrageenan on
the thrombin clotting time of plasma
to•daoOO
CO
bOG+»
-PorHo
a*H
eo
£Eh
polysaccharide concentration (mg ml )
The effect of heparin CO), alkali-modified X-carrageenan (#), t - 
carrageenan (□), l^-carrageenan (■), K -carrageenan (^ ) and 
KTf-carrageenan (A>) on the thrombin clotting of plasma. Control 
time was 22.2 ± 1 .0 s when n=3.
8 6 .
Graph A.1.8.1
The effect of heparin and carrageenan on the 
thrombin clotting time in antithrombin III 
depleted plasma
Effect of heparin CO), alkali-modified A-carrageenan CP), i 
carrageenan (□) , l ^ -carrageenan (■) , k -carrageenan (<£>) anl 
K -carrageenan (A) on the thrombin clotting time of plasma 
depleted of AT III. Control time was 50.0 ± 4.5 s when n=3
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Graph A .1.9.1
The effect of heparin and carrageenan on Factor X
(Factor Xa) amidolytid activity
Effect of heparin (O), alkali-modified X-carrageenan (#) , lN - 
carrageenan (D) , t^-carrageenan (■) , k ..-carrageen an (£>) ani 
K^-carrageenan (A) on Factor X (Factor Xa) activation. Control 
value of 0.5 ± 0.02 nm when n=3.
8 8 .
other carrageenans had no effect.
A.1.10 Thrombin-catalysed amidolytic assay
Heparin, over the range of concentrations tested, reduced thrombin 
amidolytic activity below the control value of OD = 0.52 ± 0.01 
(Graph A.1.10.1, p.90). The carrageenans had little or no effect 
on this system when measured via the end point assay.
In an attempt to elucidate the carrageenan effects on thrombin the 
experiment was repeated but, on addition of chromogenic substrate 
S2251, a recorder, attached to the spectrophotometer, was started.
The rate of paranitroaniline CpNA) released was recorded for each 
polysaccharide concentration and tracings superimposed for ease of 
comparison (Graph A.1.10.2 - A.1.10.4, p.91-93).
Heparin (Graph A.1.10.2, p. 91 ) inhibited thrombin-catalysed 
amidolysis at concentrations above 0 .0 1 mg ml * alkali-modified X- 
and i -carrageenan (Graphs A.1.10.3 - A.1.10.4, p.92 and 93)n a
both showed inhibition of thrombin-catalysed amidolysis at 1 .0  mg ml * 
only. No effects were observed with the other carrageenans.
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Graph A.1.10.1
The effect of heparin and carrageenan on thrombin-catalysed
amidolytic activity in plasma
Effect of heparin (0) ,  alkali—modified A-carrageenan (#), 1 -
carrageenan (□) , l ^ -carrageenan (■) , k -carrageenan (^ ) ancl 
^-carrageenan ( * )  on thrombin activity in plasma. Control 
value of 0.52 ± 0.01 nm when n=3 .
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Graph A.1.10.2
The effect of heparin on thrombin-catalysed amidolytic activity
determined by the measurement of the rate of reaction
reaction time(minutes)
Heparin was preincubated with plasma prior to addition of thrombin. 
The initial rate of reaction was measured when substrate was added at 
zero time. Heparin was present in the following concentrations:
----  no heparin
----  1 .0  mg ml" 1
--- - 0 .1 mg ml" 1
....  0 .0 1 mg ml" 1
----- 0.001 mg ml" 1
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Graph A.1.10.3
The effect of alkali-modified X-carrageenan on thrombin-catalysed 
amidolytic activity determined by the measurement of the
rate of reaction
Alkali-modified X-carrageenan was preincubated with plasma prior 
to the addition of thrombin then substrate was added at zero time. 
Alkali-modified X-carrageenan was present in the following final 
concentrations:
no carrageenan 
1 .0  mg ml_1 
0 .1 mg ml 
0 .0 1 mg ml 
0.001 me ml
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Graph A.1.10.4
The effect of the lNa-carrageenan on thrombin-catalysed 
amidolytic activity determined by the measurement 
of the rate of reaction
T-vg^arrageenan was preincubated with plasma prior to addition 
of thrombin then the substrate was added at zero time, l — 
Carrageenan was present in the following concentrations: Na
no carrageenan 
1 .0  mg ml0.1
0 .0 1
mg ml 
mg ml 
-- 0.001 mg ml
-1-1
-1
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A.2 Fibrinolysis
A.2.1 Euglobulin-derived fibrinolytic activity
Results (Graph A.2.1.1, p.95) show that heparin had no effect
2on fibrinolysis (control of 32.8 ± 4.1 mm ). The carrageenans 
potentiated euglobulin-derived fibrinolytic activity at a concentra­
tion of 0.1 mg ml Of the carrageenan fractions tested, K- 
carrageenan was observed to produce the greatest response with a 
four-fold increase in activity over the control value. The alkali- 
modified X- and K-carrageenan fractions increased the euglobulin 
fibrinolytic response with a 2.0 - 2.5 fold increase in fibrinolysis.
A.2.2 Inhibitor studies with £-aminocaproic acid
The incorporation ofe-ACA (2 mM) into the plasma before euglobulin
precipitation resulted in the inhibition of the alkali-modified X- and
l-carrageenan fibrinolytic response (Graph A.2.2.1, p. 96). Heparin,
as before, exhibited no effect. The K-carrageenans maintained their
fibrinolytic activity, which was maximal at 0 .1 mg ml \  with the
K-carrageenan showing greater activity than the K_ -carrageenan.K Ce2Control values were in the range 23.4 ± 1.25 mm .
A.2.3 Inhibitor studies with flufenamic acid
Flufenamic acid (12 mM), incorporated into the plasma prior to
euglobulin precipitation, resulted in fibrinolytic activity with
alkali-modified X-, lCa“> Kg-and K^-carrageenan at 0.10 mg ml 1
(Graph A.2.3.1, p.97), although no potentiation over the fibrinolytic
response observed in normal plasma was seen (Graph A.2.1.1, p.95).
Heparin had no activity in this system. Control values were
2found to be 49.3 ± 1.0 mm .
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Graph A.2.1.1
The effect of heparin and carrageenan on
euglobulin fibrinolytic activity
Effect of heparin (0), alkali-modified X-carrageenan (•) , \N - 
carrageenan (□) , 1^-carrageenan (■), K -carrageenan and
Kjj-carrageenan ''on euglobulin fibrinolytic activity. Control
area of 32.8 ± 0.1 mm^ when n=2.
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Graph A.2.2.1
The effect of g-ACA on heparin and carrageenan
derived euglobulin fibrinolytic activity
Effect of heparin (O), alkali-modified X-carrageenan (•) , -
carrageenan (□), l^-carrageenan (■), K^-carrageenan an§
KK-carrageenan (A) on plasma with e-ACA incorporated prior to 
euglobulin precipitation. Control area was 23.4 ± 1.25 mm^ 
when n=2.
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Graph A.2.3.1
The effect of flufenamic acid on heparin and carrageenan
derived euglobulin fibrinolytic activity
Effect of heparin (O), alkali-modified X-carrageenan (•), -
carrageenan O , lc&-carrageenan (■), Kc&-carrageenan ( £ $  anct 
Kj^-carrageenan (A) on plasma with flufenamic acid incorporated 
prior to euglobulin precipitation. Control area was 49.3 ± 1.0 
mm^ when n=2 .
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A.3 The kallikrein-kinin system
A.3.1 Amidolytic assay for carrageenan derived kallikrein activation
The release of paranitroaniline,as measured by spectrophotometry, 
indicates the activation of prekallikrein by the carrageenans. Only 
alkali-modified X- and l^-carrageenan fractions increased amidolysis 
at concentrations above 0.005 mg ml \  Little or no activity was 
observed with heparin or other carrageenan samples (Graph A.3.1.1 p. 99). 
Control values were in the range 0.1 ± 0.002 at A ^ g
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Graph A .3.1.1
The effect of heparin and carrageenan on the prekallikrein
as shown by amidolysis
Effect of heparin (O), alkali-modified A-carrageenan (#), iN - 
carrageenan O , iCa~carrageenan (■), Kpa-carrageenan ani
Kg-carrageenan (A) on prekallikrein amiaolytic activity. Control 
absorption was 0 .1 ± 0.002 at when n=2 .
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Blood platelet studiesA.4
A.4.1 Effect of carrageenan on platelet aggregation
In all experiments heparin and carrageenan failed to induce 
aggregation of platelets when tested in platelet-rich plasma.
Platelet samples were viewed by light microscopy and only at high poly­
saccharide concentrations (1.0 mg ml "S were clusters of 4-10 
platelets observed. These platelets showed a normal discoid shape 
with no pseudopodia evident, Introduction p. 30.
A.4.2 Effect of carrageenan on adenosine 5*-diphosphate-induced 
aggregation
No change in the aggregation response to 10 yM ADP was observed
-1in the presence of polysaccharide (range 1.0 - 0.001 mg ml ). Platelets 
viewed microscopically were seen to have a normal discoid shape with 
clusters of 4-12 platelets found only at high (1.0 mg ml 1) poly­
saccharide concentration.
A.4.3 Effect of carrageenan on thrombin-induced aggregation
A concentration of 1.0 NIH U ml * of thrombin induced a distinct 
biphasic response. The aggregation tracings obtained for each 
polysaccharide were superimposed for ease of comparison.
Heparin at all concentrations tested (1.0 - 0.001 mg ml 1), inhibited 
thrombin-induced aggregation, as shown by the absence of thrombus 
formation (Graph A.4.3.1, p.101). Alkali-modified X-carrageenan 
inhibited thrombin at concentrations of 0 .01 mg ml 1 and above 
(Graph A.4.3.2, p.102) while both 1-carrageenan salts inhibited at 
1.0 and 0.1 mg ml 1 (Graphs A.4.3.3 and A.4.3.4, p.103,104). Both 
K-carrageenans inhibited thrombin-induced aggregation at 1 .0  mg ml 
only (Graphs A.4.3.5 and A.4.3.6, p. 105,106).
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Graph A.4.3.1
The effect of heparin on thrombin-induced
platelet aggregation
Heparin was incubated with PRP for 3 minutes followed by thrombin 
(1.0 NIH U ml-1) addition at zero time.
----  control
----  heparin (1 .0 mg ml^)
— --  heparin C0 .1 mg ml^)
....  heparin (0 .0 1 mg ml_^)
----- heparin (0.001 mg ml )
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Graph A.4.3.2
The effect of alkali-modified X-carrageenan on
thrombin-induced platelet aggregation
Alkali-modified X-carrageenan was incubated with PRP for 3 minutes 
prior to the addition of thrombin (1.0 NIH U ml-'*') at zero time.
control
X-carrageenan
X-carrageenan
X-carrageenan
X-carrageenan
(1 .0 mg ml ) 
(0 .1 mg ml ) 
(0 .0 1 mg ml ) 
(0.001 mg ml )
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Graph A.4.3.3
The effect of the iNa-carrageenan on thrombin
induced platelet aggregation
1 -Carrageenan was incubated with PRP for 3 minutes prior to 
the addition of thrombin (1.0 NIH U ml“l) at zero time.
control
1^-carrageenan
l^a-carrageenan
l^a-carrageenan
l^a~carrageenan
(1.0 mg ml_.) 
(0.1 mg ml ) 
(0.01 mg ml ) 
(0.001 mg ml )
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Graph A .4.3.4
aggregation
The effect of the lpQ-carrageenan on thrombin-induced platelet
l -Carrageenan was incubated with PRP fo r 3 minutes p r io r  to  the addition  of thrombin (1.0 NIH U ml~^) at zero time.
contro l
1^-carrageenan  1 ^ -ca rrag een an  l^ -ca rrag een an  - l n -carrageenan
(1.0 mg ml ?■ )(0.1 mg ml”"-)
(0.01 mg ml ) (0.001 mg ml"1)
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Graph A .4.3.5
The effect of the KQa-carrageenan on thrombin-
induced p la te le t  aggregation
----------------- *------------------------------------ 1____________L.
0 2 4 6 8
reac tio n  time (minutes)
Kca~Carrageenan was incubated with PRP fo r 3 minutes p r io r  to  
the addition  of thrombin (1.0 NIH U ml“^) a t zero time.
con tro lK^a~carrageenan (1.0 -carrageenan (0.1 mg ml_*) mg ml_1)• v o *  *  o g c u u a u y jL • \ j^ -c a r a g e e n  :^a~carrageenan (0.01 mg ml 
^ -c a rra g e e n a n  (0.001 mg ml )
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Graph A.4.3.6
The effect of KK-carrageenan on thrombin-
induced platelet aggregation
reac tion  time (minutes)
Kj_-Carrageenan was incubated with PRP fo r 3 minutes p r io r  to  the addition  of thrombin (1.0 NIH U ml"*) a t zero time.
control
K^-carrageenan
Kg-carrageenan
K^-carrageenan
K^-carrageenan
(1 .0  mg ml ) (0.1 mg ml ) 
(0.01 mg ml _) (0.001 mg ml )
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B. Ex vivo studies
Carrageenans were in jec ted  in to  animals v ia  the intravenous, 
in trap e rito n e a l and subcutaneous rou tes and assays performed on the 
blood samples subsequently co llec ted  in order to  determine the optimum 
conditions fo r measurement of anticoagulant a c t iv i ty  and to x ic ity  
e f f e c ts .
Standard coagulation assays showed th a t the adm in istration  of 
carrageenan in tra p e rito n e a lly  re su lted  in  uptake of the carrageenan, 
and produced an anticoagulant e f fe c t without the extensive dissem inated 
in trav ascu la r coagulation found when the compounds were adm inistered 
in traveneously .
Extrapolation  of the e ffec tiv e  anticoagulant carrageenan concentra­
tio n  found in  the in  v itro  assays to  the ex vivo te s t  system re su lted  
in  a range of concentrations between 10 and 60 mg kg * a t 5 mg 
in te rv a ls  being te s te d . Further te s t s  resu lted  in  a concentration  
of 20 mg kg * being used. In each of the ex vivo te s t s  performed, 
K-carrageenans had l i t t l e  or no e f fe c t , while the most ac tiv e  c a rra ­
geenan frac tio n s  were the alkali-m odified  X- and i^ -c a rra g e e n a n . 
T h erefo re ,a ll fu rth e r stud ies were ca rried  out using these two 
carrageenans, adm inistered v ia  the perito n ea l ro u te , a t a concentra­
tio n  of 20 mg kg 1.
Route and dose of carrageenan administered
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B.l Blood clotting assay
B.1.1 P a r t ia l  throm boplastin c lo tt in g  time assay
PTT assays were carried  out on plasma obtained from carrageenan- 
tre a te d  animals. No less than fiv e  animals were used per group.
R esults i l lu s t r a te d  in  Graph B .1 .1 .1 , p. 109 in d ica te  th a t maximal 
in h ib itio n  of c lo ttin g  occurred a t 12 hours post dose fo r both 
a lka li-m odified  X- and i-carrageenan . The PTT values of samples taken 
a t 24 hours a f te r  adm inistration  of carrageenan were sim ila r to  
con tro l values. An i n i t i a l  peak was observed 2 hours a f te r  the 
adm inistration  of carrageenan.
B.1.2 R u sse ll 's  v iper venom c lo tt in g  time
The re su lts  obtained fo r the in ac tiv a tio n  of Factor X i l l u s t r a t e  
a s ig n if ic a n t anticoagulant e f fe c t w ith alkali-m odified  X-carrageenan 
over the 2-12 hour period while l i t t l e  or no a c t iv i ty  was observed 
with l-carrageenan (Graph B . l .2.1, p. 110).
Comparison of alkali-m odified  X-carrageenan e f fe c ts  on re s u l ts  
of PTT and RW assays shows a s h i f t  of g rea te s t an ticoagulan t a c tiv ity  
from 12 hours to  6 hours post dose resp ec tiv e ly .
B.1.3 Thrombin c lo ttin g  time assay
Both carrageenans were observed to  be an ticoagu lan t, with 
X-carrageenan a c tiv ity  p o ten tia ted  a t 4 hours and i—carrageenan 
maximal a t 6-12 hours (Graph B . l .3 .1 , p . l l l ) .  A value of in f in i ty  was 
obtained fo r each of seven a lka li-m odified  X-carrageenan tre a te d  
animals. As before, these re s u l ts  are taken from t r ip l i c a t e  readings 
per animal with standard erro rs  below 8.2 per cen t.
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Graph B .1.1.1
The effect of alkali-modified X- and \-carrageenan on the partial thromboplastin
c lo ttin g  time of plasma
Effect of alkali-modified X-carrageenan (#) and l-carrageenan (□) ex vivo on the PTT clotting
time of plasma. Control time of 64.8 ± 5.2 s when n >15.
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Graph B .1.2.1.
The effect of alkali-modified X- and i-carrageenan on Russell's viper venom
c lo tt in g  time of plasma
Effect of alkali-modified X- (#) and i-carrageenan (□) on R W  clotting time of plasma. Control
time was 15.2 ± 1.6 s when n >15.
Graph B.1.3.1
The effect of alkali-modified X- and l-carrageenan on the thrombin clotting time of plasma
Effect of alkali-modified ^-carrageenan (#) and l-carrageenan (□) on the thrombin clotting time
of plasma. Control time was 40.1 ± 4.2 s when n >15.
Comparison of PTT assay re s u l ts  w ith thrombin c lo tt in g  assay 
re s u l ts  suggests th a t ,  in  the case of a lka li-m odified  X-carrageenan, 
onset of anticoagulant a c tiv ity  occurs e a r l ie r  (a t 4 hours compared 
to  12 h o u rs). In the case of l-carrageenan, the antithrom botic 
e f fe c t is  sustained over the 12 hour period , re tu rn in g  to  con tro l 
value a t 24 hours.
B.1 .4  Amidolytic a c tiv ity  of Factor X (Factor Xa)
Results were obtained fo r Factor X (Factor Xa) ac tiv a tio n
shown by the am idolytic a c tiv ity  of chromogenic su b s tra te  S2222 (Methods
sec tion  1 .2 .1 ) . The a lkali-m odified  X-carrageenan f ra c tio n  was
found to  in h ib it  Factor X ac tiv a tio n  between 6-12 hours, while 1-
carrageenan exhibited  l i t t l e  or no in h ib itio n  of Factor X (Graph B .1 .4 .1 , p .  
113) .
The re su lts  obtained c o rre la te  with those of the functional 
assay using R u sse ll’s v iper venom, although the e f fe c t of carrageenan 
on Factor X d ire c tly  is  shown to  be le ss  s ig n if ic a n t using the am idolytic 
assay.
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Graph B.1.4.1
The effect of alkali-modified X- and i-carrageenan on Factor X (Factor Xa) amidolytic activity
Effect of alkali-modified X-carrageenan (•) and i-carrageenan (□) on Factor X (Factor Xa) amido­
lytic activity in plasma. Control value was 0.50 ± 0.02 nm when n > 5.
B. 2 Fibrinolysis
B.2.1 Euglobulin derived f ib r in o ly tic  a c tiv ity
A euglobulin p re c ip ita te  was obtained by a c id if ic a tio n  of 
plasma obtained from carrageenan-treated  animals. As befo re , no 
less than fiv e  animals per group were assayed, and each euglobulin 
was te s te d  in  dup licate  on f ib r in  p la te s . Results were expressed as 
the diam eter of areas of ly s is  obtained from two perpendicular axes, 
with values le ss  than the contro l in d ica tin g  in h ib itio n  of f ib r in o ly s is .
I t  was observed th a t both carrageenans in h ib ited  f ib r in o ly s is  (Graph 
B .2 .1 .1 , p .115). The i-carrag een an -trea ted  animals showed in h ib itio n  
a t 2 hours while alkali-m odified  X -carrageenan-treated animals 
in h ib ited  f ib r in o ly s is  between 2 and 6 hours, g rea te s t in h ib itio n  
occurring a t 6 hours.
B.2.2 In h ib ito r stud ies with e-aminocaproic acid
Plasma obtained from carrageenan-treated  animals was incubated 
with e-ACA (2 mM) p rio r  to  the formation of the euglobulin p re c ip i ta te .
As previously  s ta ted ,d u p lic a te  assays were ca rried  out on each 
euglobulin fra c tio n .
1 -Carrageenan produced no s ig n if ic a n t d iffe ren ce  between con tro l and 
te s t  values (Graph B .2 .2 .1, p.116). The plasma euglobulin derived from 
alkali-m odified  X-carrageenan tre a te d  animals was in h ib ito ry  to  
f ib r in o ly s is  over the 2-4 hour period w ith no s t a t i s t i c a l l y  s ig n if ic a n t 
d ifffe ren ce  a t 6 hours.
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Graph B .2.1.1
f ib r in o ly tic  a c tiv ity
The effect of alkali-modified X- and \-carrageenan on plasma euglobulin
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Graph B.2.2.1
The effect of alkali-modified A- and x-carrageenan on euglobulin-derived
f ib r in o ly tic  a c tiv ity  in the presence of £-aminocaproic acid
Effect of alkali-modified A-carrageenan (#) and i-carrageenan (□) on euglobulin-derived fibrino­
lytic activity in the presence of e-ACA (2 mM) . Control value was 153.0 ± 17.5 mm^ when n >5.
B.2.3 Inhibitor studies with flufeiiamic acid
The incorporation  of flufenamic acid in to  carrageenan-treated  
plasma p rio r  to  euglobulin p re c ip ita tio n  re su lted  in  in h ib itio n  of 
f ib r in o ly s is  peaking a t 2 hours, re tu rn ing  to  con tro l f ib r in o ly t ic  
a c tiv ity  at 4 hours (Graph B .2 .3 .1 , p. 118).
Comparison with normal f ib r in o ly tic  a c tiv ity  showed th a t 
flufenamic acid had l i t t l e  or no e ffe c t on l-carrag een an -trea ted  
plasma, whereas the a c tiv ity  of alkali-m odified  X-carrageenan was 
reduced.
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Graph B.2.3.1
a c tiv ity  in the presence of flufenamic acid
The effect of alkali-modified A- and i-carrageenan on euglobulin-derived fibrinolytic
hours post dose
Effect of alkali-modified A“carrageenan (#) and i-carrageenan (CD on euglobulin-derived fibrino
lytic activity in the presence of flufenamic acid (12 mM). Control value was 150.0 ± 20.0 mm^
when n >5.
B.3 Kallikrein-kinin system
B.3.1 Amidolytic assay fo r carrageenan derived p re k a llik re in  
ac tiv a tio n
To observe the e f fe c t of carrageenan on the ac tiv a tio n  of plasma 
p re k a llik re in , plasma obtained from carrageenan-treated  animals was 
assayed using the chromogenic su b s tra te  S2302. The conversion of 
p rek a llik re in  to  the p ro teinase k a ll ik re in  re su lted  in  the re lea se  
of pNA from the su b s tra te  and the re su lta n t colour change was measured 
spectrophotom etrically .
A dm inistration of carrageenan re su lted  in increased am idolysis 
over the i n i t i a l  4 hour period, but in h ib itio n  over 12-24 hours 
(Graph B .3 .1 .1 , p. 120). The plasma of a lka li-m odified  A-carrageenan- 
tre a te d  animals showed g rea ter am idolysis than th a t of 1-carrageenan 
but le s s  in h ib itio n  over the 12-24 hour period . The p re k a llik re in -  
catalysed am idolytic ra te s  observed in  plasma samples taken from 
both groups of animals returned to  normal lev e ls  w ithin  36 hours.
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Graph B .3.1.1
The effect of alkali-modified A- and 1-carrageenan on prekallikrein
E ffect of alkali-m odified  A-carrageenan (•)' and t-c a r  r  ageenan^n p rek a llik re in  using chromoeenic su b stra te  S2302. Control absorbance was 0.5 ± 0.01 when n >5. s
B. 4 Platelet studies
B.4.1 P la te le t  counts in  p la te le t - r ic h  plasma
P la te le t  counts were ca rried  out on PRP samples. Results
expressed in  Graph B .4 .1 .1  (p. 122) i l l u s t r a t e  the mean and standard
e rro rs  fo r no less  than fiv e  animals per group with a con tro l value of 
5 -3 52.7 x 10 p la te le ts  mm i  0.2 x 10 . Standard e rro rs  were w ithin  
the range 2-19 per c e n t.
Both alkali-m odified  X- and i -carrageenan suppressed the 
p la te le t  count, w ith only l-carrageeenan -treated  animals re tu rn in g  
to  normal a t 36 hours post dose.
B.4.2 Adenosine 5 '-diphosphate-induced aggregation
P la te le t  aggregation was ca rried  out as previously  described 
(Methods Section 4 .2 ). As before, no le ss  than f iv e  animals per group 
were used. The ADP a c tiv ity  was assessed using th ree  concentrations 
on dup licate  p la te le t  samples.
Graph B .4 .2 .1(a) (p. 123) i l lu s t r a te s  a ty p ica l con tro l aggregation 
response while Graphs B .4 .2 .1(b) and (c) (p. 123) show the influence of 
1 -  and alkali-m odified  X-carrageenan resp ec tiv e ly  on ADP-induced aggregation 
4 hours post dose. In a l l  cases f i r s t  phase re v e rs ib le  aggregation 
was observed.
Results of aggregation induced by 1.0 |iM ADP ind ica ted  a 
contro l value of 58 . t  4 .4 per c e n t. Aggregation values below 58 per cent 
in d ica te  in h ib itio n . I t  was observed th a t over a time period of 2-36 
hours alkali-m odified  X-carrageenan s ig n if ic a n tly  in h ib ited  ADP-induced 
aggregation, reducing the ADP response to  6.4 per cent of normal 
(Graph B .4 .2 .2, p. 124). l-Carrageenan also  caused
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Graph B.4.1.1
The effect of alkali-modified A- and i-carrageenan on platelet counts
The e ffec t of a lkali-m odified  A-carrageenan (•) and i-carrageenan (□ ) on p la te le t  counts. Control 
p la te le t  count of 2.7 ± 0.2 x 105 mm3 when n >5.
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Graph B.4.2.1
Aggregation responses to  ADP at 4 hours post dose
E ffect of carrageenan on ADP induced aggregation a t 4 hours 
(a) normal response (b) i-carrageenan (c) a lka li-m odified  X- 
carrageenan.
------- 50 PM ADP
____  10 PM ADP
------  1.0 PM ADP
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Graph B.4.2.2
The effect of alkali-modified A- and 1-carrageenan on ADP induced platelet aggregation
E ffect of alkali-m odified  A-carrageenan(#) and 1-carrageenan (□ ) on p la te le t  responsiveness to  ADP (1.0 ]iM). Control value was 58 ± 4.4 per cent when n >5.
in h ib itio n  of ADP-induced aggregation. However, in  th is  case, onset 
of in h ib itio n  occurred a t 6 hours and the response to  ADP treatm ent 
returned to normal a t 24 hours.
At an ADP concentration of 10 yM, a con tro l value of 72.5 t  6.4 
per cent was observed (Graph B .4 .2 .3 , p. 126). At lower ADP concentra­
tio n s , alkali-m odified  A-carrageenan in h ib ited  ADP-induced aggregation 
but to  a le s se r  degree in  both ex ten t and duration  of p la te le t  in h ib itio n  
a t 6-12 hours. A small peak was observed a t 4 hours.
A f in a l concentration  of 50 yM ADP resu lted  in  a con tro l value 
of 82.5 t  5.2 per cent aggregation. The aggregation response was 
s t i l l  re v e rs ib le , showing no in d ica tion  of second phase aggregation 
even when p la te le ts  were l e f t  s t i r r in g  a t 900 rpm fo r 30 minutes.
Results i l lu s t r a te d  on Graph B .4 .2 .4  (p. 127) suggested th a t both 
carrageenans exerted an a n t ip la te le t  e f fe c t w ith respec t to  ADP-induced 
p la te le t  aggregation. As before with the functional c lo tt in g  assays,
\-carrageenan exhib ited  a delay of 6 hours p rio r  to  onset of an in h ib ito ry  
response. The extent of in h ib itio n  during the 6-12 hour period was 
s ig n if ic a n t. The alkali-m odified  A-carrageenan showed an in h ib ito ry  
response, peaking a t 4 hours and re tu rn ing  to normal w ithin  the 12-24 
hour period.
B.4.3 Thrombin-induced aggregation
The influence of thrombin on the p la te le ts  of carrageenan-treated  
animals was assayed by the add ition  of thrombin to  PRP and measurement 
of the aggregation response over a 10 minute period . Graph B .4 .3 .1 (a)
(p. 128) i l lu s t r a te s  a ty p ica l thrombin-induced response in s a lin e -  
tre a ted  animals, and Graphs B .4 .3 .1(b) and (c) (p. 128) show the 
influence of 1- and alkali-m odified  A-carrageenan resp ec tiv e ly  a t 
4 hours post dose.
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Graph B.4.2.3
The effect of alkali-modified A- and i-carrageenan on ADP-induced platelet aggregation
E ffect of alkali-m odified  A-carrageenan (•) and i -carrageenan (□ ) on p la te le t  responsiveness 
to  ADP (10 yM) . Control value was 72.5 ± 6.4 per cent when n >5.
Graph B.4.2.4
The effect of alkali-modified A- and l-carrageenan in vivo on ADP-iriduced platelet aggregation
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Graph B.4.3.1
Aggregation responses to thrombin at 4 hours post dose
(a) 100
80
60
40
20
0
(b) 100
80
60
40
20
0
E ffect of carrageenan on thrombin induced aggregation a t 4 hours 
Ca) normal response (b) l-carrageenan (c) a lkali-m odified  X- 
carrageenan.
1.5 NIH U ml”?” thrombin 1.25 NIH U m il1 thrombin 
1.0 NIH U ml 1 thrombin
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Thrombin a t 1.0 NIH U ml 1 produced re v e rs ib le  aggregation in 
sa lin e - tre a te d  animals re su ltin g  in  60 per cent aggregation. At 
4 hours, a lkali-m odified  X-carrageenan reduced the thrombin response 
to  17 per c e n t, the response re tu rn in g  to  normal lev e l a t 6 hours 
(Graph B .4 .3 .2 , p. 130). Onset of i-carrageenan a n t ip la te le t  e f fe c t 
occurred a t 6-12 hours, with a normal response occurring a t 24 hours.
A thrombin concentration of 1.25 NIH U ml * re su lted  in a d is t in c t  
f i r s t  phase of aggregation, followed by second phase with thrombus 
formation. In both cases, the carrageenans exerted a potent a n t i ­
thrombotic e f fe c t in the 2-12 hour period (Graph B .4 .3 .3 , p. 131).
The in h ib ito ry  e f fe c t of l-carrageenan was observed to  be g rea te r 
than th a t of alkali-m odified  X-carrageenan, with a value as low 
as 26 per cent a t 4 hours.
A thrombin concentration to  1.5 NIH U ml  ^ produced second 
phase ir re v e rs ib le  aggregation in  plasma from sa lin e - tre a te d  animals. 
With alkali-m odified  X-carrageenan, in h ib itio n  of thrombin a c t iv i ty  
was maximal a t 6 hours (Graph B .4 .3 .4 , p. 132). This e f fe c t was 
maintained over a 2-12 hour period, w ith only 8-11 per cent aggregation 
being observed. With i-carrageenan, in h ib itio n  of thrombin a c t iv i ty  
was seen only between 4-6 hours.
B.4.4 P la te le t  adhesiveness stud ies
The assay fo r p la te le t  adhesiveness was devised to  gauge the 
influence of carrageenans on the induction of p la te le t  ’’s t ic k in e s s " .
Both carrageenans administered were shown to  decrease p la te le t  adhesive­
ness over an i n i t i a l  2-4 hour period , with the i-carrageenan e f fe c t 
extended to  12 hours (Graph B .4 .4 .1 , p. 133).
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Graph B.4.3.2
The effect of alkali-modified X- and i-carrageenan on thrombin-induced aggregation
Effect of alkali-modified X-carrageenan (•) and i-carrageenan (□) on platelet responsiveness to
thrombin (1.0 NIH U ml“^). Control value was 58.0 ± 12.5 per cent when n >5.
Graph B.4.3.3
The effect of alkali-modified X- and i-carrageenan on thrombin-induced platelet aggregation
Effect of alkali-modified A-carrageenan (#) and x-carrageenan (□) on platelet responsiveness to
thrombin (1.25 NIH U ml“l). Control value was 100 per cent when n >5.
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Graph B.4.3.4
The effect of alkali-modified X- and \-carrageenan on thrombin-induced platolot aggregation
Effect of alkali-modified X-carrageenan (#) and i-carrageenan (□) on platelet responsiveness to
thrombin (1.5 NIH U ml“ -^). Control value was 100 per cent when n >5.
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Graph B.4.4.1
The effect of alkali-modified X- and 1-carrageenan on platelet adhesiveness
Effect of alkali-modified X-carrageenan (•) and 1-carrageenan (□) on platelet adhesiveness following
carrageenan administration. Control value was 34.8 ± 2.0 per cent when n >5.
When platelets were observed microscopically over the
2 and 6 hour period they were found to  be normal. In a few 
in stances, p la te le ts  were seen to  have agg lu tinated . At 4 hours, 
however, p la te le ts  obtained from alkali-m odified  A-carrageenan- 
tre a te d  animals were found to  have an ir re g u la r  shape unlike e ith e r  
a normal or ac tiva ted  p la te le t .  The c e lls  were observed to  be highly 
ir re g u la r  in  shape and d i f f ic u l t  to  count. The p la te le ts  had 
returned to  normal in  samples obtained from animals 6 hours post 
in jec tio n . In these alkali-m odified  A -treated animals, there  was 
an increase in p la te le t  adhesiveness a t 6 hours; however, p la te le ts  
had returned to  normal w ithin a 12 hour period.
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B.5 The immune response
B.5.1 Antigen concentration  in  serum
Maximum antibody response to  sheep red blood c e l ls  (SRBC) in jec ted
i  ,p . was achieved a t 4 x 1 0 ^  c e lls  kg 1 (Graph B .5 .1 .1 , p. 136).
10Comparison with l i t e r a tu r e  re su lted  in  a value of 2.5 x 10 c e l ls  
kg  ^ being used to  avoid to lerance induction (Thomson et_ a l^ , 1981; 
Schneidkraut and Loegering, 1981).
B .5 .2 Antibody response to  i-carrageenan adm in istration
Results i l lu s t r a te d  on Graph B .5 .2.1 (p. 137) ind icated  th a t 1- 
carrageenan in jec ted  i , p . 24 hours before antigen (2.5 x 1 0 ^  c e l ls  
kg 1 , i . p . ) was immunosuppressive a t a l l  concentrations adm inistered.
Post mortem in v estig a tio n  of a l l  animals showed no immediately 
obvious patho log ical abnorm alities except in  animals receiv ing  
40-60 mg kg 1 where several white plaques of 2-3 mm diameter were 
loosely adherent to  the l iv e r  surface and s im ila r m ateria l had 
converged and formed a large d isc re te  sac round the caudate lobe 
of l iv e r .  Inflammation of the duodenum was evident in  some of 
these animals.
H isto log ica l examination of the l iv e r  showed th a t the sac was 
surrounded by a continuous mesoendothelial sheath. There was 
no d is t in c t  o rgan isation  of c e lls  with the sac, but large m ulti- 
nucleated macrophages containing carrageenan were observed attached 
to ,o r  ly ing close to ,a rea s  of carrageenan. Somecellular debris 
due to  ly s is  was evident as were ac tiv e ly  p ro life ra tin g  f ib ro b la s ts  
and polymorphs. Sim ilar observations were made with sections of the 
duodenum, the only d ifference being th a t the inflammatory response
135.
Re
ci
pr
oc
al
 o
f 
ha
em
ag
gl
ut
in
at
io
n 
ti
tr
e
G raph B . 5 . 1 . 1
The e f f e c t  o f  a n t ig e n  on in d u c t io n  o f  th e  immune re s p o n s e
Effect of x-carrageenan on antibody titres to concentrations 
of sheep red blood cells injected i.p. Each bar represents 
the mean + S.E. of 5 animals 8 days after antigen.
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G raph B . 5 . 2 . 1
The effect of i-carrageenan on antibody 
titres to sheep red blood cells
Effect of various concentrations of i-carrageenan administered 
i .p. 24 hours prior to antigen (2.5 x 1010 SRBC kg-1, i,p.) 
as assayed by the 8 day haemagglutination response. Each bar 
represents the mean + S.E. of 5 animals.
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was present within the tissue and infiltrating blood vessels were 
seen to contain many inflammatory cells.
B.5.3 Total immunoglobulin levels
Serum from the previous experiment was assayed for total IgM 
and IgG levels by the enzyme-linked immunosorbent assay (ELISA) .
Results were obtained and expressed as ratios where a value less than 
1.0 indicated suppression of the total IgM and IgG level. A trend 
similar to that of the haemagglutination assay was observed with 
total IgM and IgG levels (Graph B.5.3.1, p. 139).
B.5.4 The time of carrageenan injection in relation to antigen
Results expressed on Graph B.5.4.1 (p. 140) indicate that the time 
of injection of carrageenan in relation to antigen administration had 
no statistical significance when assayed by both the eight day 
haemagglutination assay and ELISA (Graphs B.5.4.1 and B.5.4.2, p. 140 
and p. 141). The control level of this and subsequent repeat assays was 
found to be extremely low in comparison with previous experiments, 
thus the results obtained were invalid.
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G raph B . 5 . 3 . 1
The e f f e c t  o f  i - c a r r a g e e n a n  on t o t a l  im m u n o g lo b u lin  le v e ls
5 10 20 40 60
carrageenan dose (mg kg”1)
Effect of l-carrageenan on total I g M ^ a n d  IgG I f 
levels as assayed by ELISA. Each histogram represents 
the mean of 5 animals per group.
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G raph B . 5 . 4 . 1
l h-g..,± f f e c t  o f  1 - c a r r ageenan on a n t ib o d y  t i t r e s  when in je c t e d  in  r e l a t i o n  to  a n t ig e n
Effect of i-carrageenan (20 mg kg * i,p.) on the antibody titre when injected in relation to time of 
antigen (2.5 x 101® SRBC kg-1) as assayed by the 8 day haemagglutination assay.
G raph B . 5 . 4 . 2
The e f f e c t  o f  i - c a r r a g e e n a n  on IgM  and IgG  le v e ls  in  resp o n se  to  sheep re d  b lo o d  c e l l s
days pre-SRBC
tofs ™ c ° y r r^ ~  (t°-if k!_1) °“ Ig“ 0  aDd IgG □  levels in serura in response to SRBC (2.5 x 10 cells kg x) when administered pre-SRBC.
B. 6 L ip r o p r o t e in  assay
B.6.1 Serum lipoprotein studies
Four principal lipoprotein fractions, very low density lipo­
protein (VLDL), intermediate density liproprotein (IDL), low density 
liproprotein (LDL) and high density lipoprotein (HDL) were separated 
by density ultracentrifugation and total cholesterol measured against 
a standard curve of cholesterol (Graph B.6.1a, p. 143). With alkali- 
modified X-carrageenan-treated animals very high levels of VLDL and IDL 
were observed at 0-2 hours, with VLDL again maximal over the 6-12 hour 
period. Elevation of LDL occurred at 2 hours and 12 hoursbut no 
significant change was observed with HDL levels (Graphs B.6.1.1 - 
B.6.1.4, p. 143-146).
The serum from 1-carrageenan-treated animals indicated that this 
carrageenan had no effect on VLDL levels but increased IDL, LDL and 
HDL levels at 6 hours. The levels returned to normal at 24 hours 
(Graphs B.6.1.1 - B.6.1.4, p. 143-146)
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G raph B .6 .1 a
Standard curve of cholesterol for lipoprotein assays
Cholesterol (mg/100 ml)
G raph B . 6 . 1 . 1
The e f f e c t  o f  a l k a l i - m o d i f i e d  A - and i -c a r r a g e e n a n  On serum  v e r y  low  d e n s ity  l ip o p r o t e in  le v e ls
E f f e c t  o f  a l k a l i - m o d i f i e d  A -c a rra g e e n a n  ( • )  and l -c a r r a g e e n a n  O  on serum VLDL l e v e l s .
G raph B . 6 . 1 . 2
The e f f e c t  o f  a lk a l i - m o d i f i e d  X - and l -c a r r a g e e n a n  on serum  in te r m e d ia te  d e n s ity  l ip o p r o t e in  l e v e ls
G raph B . 6 . 1 . 3
The e f f e c t  o f  X - and t -c a r r a g e e n a n  on serum  low  d e n s ity  l ip o p r o t e in  l e v e ls
E f f e c t  o f  a lk a l i - m o d i f i e d  X -c a rra g e e n a n  ( • )  and l -c a r r a g e e n a n  (Q ) on serum  LDL l e v e l s .
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G raph B . 6 . 1 . 4
The e f f e c t  o f  a l k a l i - m o d i f i e d  A - and i-c a r r a g e e n a n  on serum  h ig h  d e n s ity  l ip o p r o t e in  l e v e ls
2 4
E f f e c t  o f  a l k a l i - m o d i f i e d  A -c a rra g e e n a n  (# )  and i -c a r r a g e e n a n  (□ )  on serum HDL l e v e l s .
V D IS C U S S IO N
1. Blood clotting
Carrageenans were used in the present study to investigate their 
effects on the pathways and cell systems of blood coagulation 
centering on Factor XII activation. By selection of appropriate 
in vitro assays, carrageenans were shown to have effects primarily 
as anticoagulants (Graphs A.1.1.1 - A.1.8.1, p. 78 and 87). Extension 
of the studies to examine carrageenan effects following administra­
tion to rats showed the alkali-modified A-carrageenan and - carra-Na
geenan to possess the most anticoaglulant activity of the fractions 
tested (Results, p. 107).
With respect to carrageenan effects,route of administration will 
influence absorption and distribution of the polysaccharides within the 
body fluids. Not least of all is the interaction of these polyelectro­
lytes with both humoral and cellular elements within the peritoneal 
cavity. The potential interactions which could take place are as 
follows: Carrageenan, as an anionic electrolyte, would be expected
to associate directly with positively-charged plasma proteins yielding 
a macroionic complex. Proteins are amphoteric polyelectrolytes and 
depending on their isoelectric points may be more negatively or 
positively-charged at physiological pH. Direct interaction of the 
proteins which are positively-charged with the negatively-charged 
carrageenan could therefore occur (Comper and Laurent, 1978).
The occurrence of the anionic groups at frequent intervals along 
the polyelectrolyte chain results in the sharing of charge. Hence 
the carrageenan has a shell of negative charges of greater or lesser
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density along its length, rather than individual point charges. The 
overall conformation of the carrageenan may also be influenced by 
the particular salt formation which could considerably influence 
potential interactions with plasma proteins, for example, the calcium 
salt of the carrageenan where the calcium ion forms a bridge between 
negatively-charged proteins and the negatively-charged carrageenan. 
Alkali-modified X-carrageenan, largely a linear conformation, may act 
in a similar manner to any negatively-charged surface such as glass 
or kaolin, and may form a template for protein alignment. 1 -Carrageenans 
in some studies may adopt a helical structure in which chains are 
held by electrostatic and hydrogen bonding (Rees, 1961). This 
structure forms a more viscous gel matrix compared to the alkali- 
modified X-carrageenan. The K-carrageenans form yet more gel networks, 
again by interchain bondings (Chakraborty and Hansen, 1971); however, 
proteins may bind at the interconnecting strands between helices 
resulting in the stabilisation of the protein (Figure B.l, p. 150).
With a negatively-charged galactan sulphate and a positively- 
charged protein moiety,electrostatic interactions take place between 
the sulphate half-esters of the galactose unit and the protonated N- 
terminal amino group on the protein. Alignment may not be total, and 
intermediate or transitional degrees of association may occur due 
both to electrical interaction and structural compatibility.
When examined in functional blood clotting assays, heparin and 
carrageenans, with the exception of K-carrageenan,were anticoagulant 
in vitro (Graphs A.1.1.1 to A.1.8.1, p. 78 to 87). Other authors 
observed similar responses (Ratnoff, 1954; Hawkins and Leonard, 1963; 
Anderson and Duncan, 1965; Kindness, Long and Williamson, 1980a).
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When carrageenan was injected into the peritoneum, maximal
anticoagulant effects were found with the alkali-modified X-carrageenan
and the -carrageenan; therefore, studies ex vivo were centered on Na -------
these two carrageenans in an attempt to investigate the carrageenan 
influence on the blood coagulation pathways.
The in vitro studies showed that the carrageenans activated 
Factor XII but that this effect was obscured by the anticoagulant 
effect exerted by the same compounds (Graph A.1.2.1, p. 79).
Because heparin, a mammalian sulphated polysaccharide of superficially 
similar structure to carrageenan, is a well-known anticoagulant, 
effects of carrageenan and heparin on blood clotting were compared.
It was initially suggested by Rosenberg and Damus (1973) that heparin 
affected the early stages of the intrinsic pathway of coagulation 
by interacting with the proteinase inhibitor antithrombin III (AT III) 
which accelerates the neutralisation of Factors XII, IX,X, XI and 
thrombin. Heparin also interacts directly with thrombin (Kindness, 
Long and Williamson, 1980a) although Gitel (1978) showed that the 
binding of thrombin to heparin was less strong than that of thrombin 
to AT III.
Within this study, in vitro assays showed that removal of 
AT III from plasma reduced the carrageenan influence on thrombin 
(Graph A.1.7.1, p. 86) but had little effect on the carrageenan 
influence on Factor X (Xa) (Graph A.1.6.1, p. 85). Hence, carrageenans 
could act in a heparin-like manner via complex formation with AT III 
but also inhibit anticoagulant activity independent of AT III as 
shown in studies employing AT Ill-depleted plasma (Graph A.1.8.1, p. 87)
Carrageenans studied ex vivo showed anticoagulant effects when 
assayed by thrombin clotting time but only the alkali-modified X-
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carrageenan was anticoagulant at a Factor XII and Factor X (Xa) level 
(Graphs B.1.1.1 to B.1.3.1, p.109 to 111) . These results, in conduction 
with the in vitro results, may be explained in the following way:-
The carrageenans could act in a structure-dependant manner 
through complex formation with suitable plasma proteins and as HMWK 
and fibrinogen via appropriate binding groups. The alkali-modified 
X-carrageenan may essentially be a straight-chained molecule which 
may form a suitable matrix on which serine proteinases and/or their 
substrates or inhibitors may align.
The i- and K-carrageenans form viscous gel matrices and, although 
highly negatively-charged on the surface of the matrix, the internal 
negative charges may be masked. Hence, interaction with proteinases 
or their inhibitors may be reduced compared with the alkali-modified 
X-carrageenan.
The activity of the carrageenans as electrolytes should also be 
considered; alignment of the positively-charged proteins along a 
negatively-charged particle would be more efficient the greater the 
charge density. It would therefore follow that the alkali-modified 
X-carrageenan would be more anticoagulant than either the x- or 
K-carrageenans. However, in a large number of the assays within this 
thesis, the alkali-modified X-carrageenan was not the most active 
anticoagulant so charge density may not be the only contributing factor.
Studies have been carried out on heparin-protein interactions 
(Blackwell, Schodt and Gelman, 1977). These authors found that heparin 
caused conformational changes within the protein, primarily at the active 
site where high charge density occurs. This conformational change 
induced by heparin was found to alter the biological activity of the 
protein.
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Studies with AT III, showed that heparin increases the activity 
of AT III towards thrombin neutralisation (Abildgaard, 1969). It 
was found by Hopwood eit _al. (1976) that segments of certain heparin 
chains contained AT Ill-binding sites of high affinity. How often 
these sites occurred per heparin chain could be determined by length 
and selection of the required disaccharide units. This concept that 
heterogeneous regions along the chain are important, in determining or 
controlling binding with selected plasma proteins and hence the 
biological activity of the galactan sulphates, emerges from these 
studies (Hopwood et aJ. , 1976). Also,affinity for a given complex 
will not only depend on the strength of the electrostatic interaction 
but also on the closeness of fit of the two molecules (Jacques, 1979).
These hypotheses may be applied to the results of the amidolytic 
assays carried out in vitro and ex vivo for Factor X (Xa) and thrombin. 
The carrageenans were found not to directly affect the rate of Factor X 
(Xa) amidolysis in vitro (Graph A.1.9.1, p. 88), but ex vivo slight 
inhibition occurred at 12 hours post carrageenan administration with 
both the carrageenan fractions studied (Graph B.1.4.1, p. 113). Thrombin 
amidolysis was inhibited by all concentrations of heparin but by only 
high carrageenan concentrations in vitro (Graphs A.1.10.2 to A.1.10.4, 
p.91 to 93 ). This type of assay again highlights the difference 
between a functional clotting assay which takes into account factors 
other than that being directly examined and one which is more specific, 
such as the amidolytic assay, where only the direct activation of a 
serine proteinase is being studied.
Putative effects of the carrageenans on the intrinsic pathway 
of coagulation may be summarised by stating that there is a carrageenan 
interaction with Factor XII, Factor X and thrombin. The interaction
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may be dependent on AT Ill-neutralisation of thrombin but no AT III
involvement was observed with Factor X. This effect may prevent
cleavage of fibrinogen to fibrin, resulting in an anticoagulant
effect along with a reduction in FDP production and concomitant
reduction in the response to an antigen. In ex vivo assays, alkali-
modified A-carrageenan was more anticoagulant than the -carrageenanNa
fraction, possibly due to the alkali-modified A-carrageenan being of 
a higher charge density and therefore a more suitable electrolyte.
The i-carrageenan was found to act primarily in the neutralisation of 
the proteinase thrombin and correlation with in vitro results suggests 
that AT III may bind to specific areas of the molecule resulting in 
the increased activity of the antiprotease towards thrombin.
This thesis is based on the pathways associated with Factor XII 
activation and so the study was continued to ascertain the effects 
of carrageenan on fibrinolysis.
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2 .  F i b r i n o l y s i s
Spontaneous generation of fibrinolytic activity iii vitro or 
ex vivo could not be demonstrated in normal rat plasma. Only by 
acidification of the plasma, with the subsequent formation of a 
euglobulin precipitate, was it possible to show carrageenan 
activation of the fibrinolytic pathway. Euglobulin precipitation 
per se removes the vast majority of the inhibitors of fibrinolytic 
activity; however, proteins such as Cl inhibitor may precipitate 
with the euglobulin fraction,resulting in Factor Xlla neutralisation 
by its complex formation with the inhibitor (Kluft, Brakman and 
Veldhuyzen-Stalk, 1976).
In the in vitro studies, addition of carrageenan to plasma before 
euglobulin precipitation resulted in an increase in fibrinolytic 
activity which was shown to be dependent on the concentration of 
carrageenan used. Maximal activity was found at 0.1 mg ml * with the 
K-carrageenan (Graph A.2.1.1, p. 95). This type of response to 
carrageenan was also found in human plasma (Kindness, 1979) with the 
higher concentration of test galactan, the reduced fibrinolytic response 
may have been due to two effects. As the euglobulin fraction was 
formed, the ionic polymers may have co-precipitated with fibrinolytic 
inhibitors such as Cl inhibitor and histidine-rich glycoprotein (Lijnen, 
Rylatt and Collen, 1983). Similarly, at the optimum test concentration 
for fibrinolysis, sequestration of free inhibitor by the polyanions 
could allow cleavage of plasminogen in an inhibitor-free environment.
The pH required to obtain maximal control fibrinolysis was found 
in this thesis to be lower for rat than for human plasma (Kindness,
1970). The method of euglobulin precipitation using low pH may not
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be ideal, since additional plasma proteins could be required for 
fibrinolysis and could remain in the supernatant following euglobulin 
precipitation. Similarly ,-during addification of plasma the charge 
effect on the protein may have been altered resulting in the potential 
activator being precipitated or neutralised during complex formation.
This view may be supported by the finding that fibrinolysis, ex vivo, 
was found to be inhibited by carrageenan (Graph B.2.1.1, p.115). At 
2 hours post dose i-carrageenan showed maximal inhibition while 
the alkali-modified X-carrageenan effect ranged over the 2-6 hour 
period with optimal inhibition at 6 hours.
In an attempt to determine the sites at which carrageenan might 
be affecting the fibrinolytic pathway, e-ACA, an inhibitor of plasminogen, 
was incorporated into plasma samples prior to euglobulin precipitation.
The e-ACA binds to plasminogen and inhibits its activation. Results 
expressed on Graph A.2.2.1, (p. 96 ) for in vitro studies showed that 
e-ACA did decrease fibrinolytic activity. The carrageenan effect was 
reduced except in the case of the K-carrageenan fractions where fibrino­
lytic activity increased two-fold over that detected in normal plasma.
When e-ACA was incorporated into ex vivo plasma samples a decrease 
in the fibrinolytic inhibitory response resulted (Graph B.2.3.1, p.118). 
These results illustrate that the K-carrageenan iji vitro may inhibit 
the binding of e-ACA to the plasminogen, possibly through a mechanism 
in which plasminogen is trapped in the interconnecting stands of the 
galactan sulphate gel matrix. This type of interaction may not occur 
with the other carrageenan structures. Alternatively, the K-carrageenan 
may form the closest fit to the active site of the plasminogen, 
rendering it less susceptible to inhibitors in the plasma. Euglobulin
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precipitation would then remove the inhibitor into the supernatant, 
allowing action of the proteinase on the fibrin plate.
Flufenamic acid inhibits Cl inhibitor activity,therefore 
increasing the fibrinolytic activity since Cl inhibitor inhibits 
plasmin action on fibrin (Donaldson and Harrison, 1982). ^n vitro, 
flufenamic acid increased only the K-carragenan induced fibrinolytic 
activity whilst ex vivo samples from alkali-modified X-carrageenan 
treated plasma euglobulin showed decreased fibrinolysis at 4-6 hours 
post dose. These results suggest that Cl inhibitor plays an important 
part in the regulation of fibrinolysis both in vitro and ex vivo.
The K-carrageenan, as with e-ACA, may bind competitively to the Cl 
inhibitor binding site thus initiating an increase in fibrinolysis.
The carrageenan jin vitro could activate Factor XII and hence 
trigger plasminogen proactivator and prekallikrein along with the 
coagulation cascade (Kluft, 1978b). Carrageenan may cause precipitation 
of proteins such as Cl inhibitor into the euglobulin precipitate and 
on resolublisation of the precipitate, the inhibitor would be 
released into the supernatant to bind to plasminogen.
Alternatively,studies have been carried out with K-carrageenan 
that illustrate how this polymer binds and protects proteins (Chakraborty 
and Hansen, 1971). The K-carrageenan strands gel to form bundles of 
helices with no ability to react with protein. The loose ends of the 
helices serve as junction zones to connect other strands which form 
a three dimensional network and may trap protein molecules. In the 
euglobulin precipitation the K-carrageenan may take up plasminogen 
activator at its junction zones and release the proteins into the 
supernatant on resolubilisation. Since the proteins have been protected
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from the external environment no denaturation occurs. This could 
explain why K-carrageenans are so highly fibrinolytic in vitro.
The in vitro studies showed that the carrageenan fibrinolytic 
response was concentration-dependent and this may explain the response 
observed ex vivo. Insufficient carrageenan may have been present in the 
circulation to induce a fibrinolytic response. Also,the carrageenan 
in vivo may cause changes in the precipitation pattern of the proteins 
and in the amount of plasminogen and activators recovered in the euglobulin 
fraction. That is, the carrageenan in vivo may decrease the plasminogen 
ability to precipitate in the euglobulin fraction. Alternatively, 
it may increase the activity and precipitation of inhibitors, primarily 
Cl inhibitor.
In summary, the carrageenans were observed to be fibrinolytic 
in vitro, with «-carrageenan fractions having greatest activity. This 
activity was found to be doncentration-dependent, an observation which 
may explain the ex vivo inhibitory action of carrageenan on fibrinolysis. 
The results may be related to the polymer structure of the galactan 
sulphates and also their electrostatic interactions with proteins and free 
cations.
As stated earlier, p . 157,carrageenan could potentially interact with 
either Cl inhibitor or with a plasminogen activator and Cl inhibitor and 
plasmin could influence Factor Xll-mediated responses. A direct 
correlation exists between Factor XII and the kallikrein-kinin system 
where kallikrein is known to be intimately involved in inflammatory 
reactions. Carrageenans have also been shown to induce inflammatory 
reactions and thus, the next step in the investigation centered on the 
kallikrein-kinin pathway.
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3 . K a l l i k r e i n - k i n i n  system
The carrageenans investigated ex vivo potentiated prekallikrein- 
catalysed amidolysis over the initial 4 hour period but inhibited 
activity at 12-24 hours, the rates of amidolysis measured returning 
to control value at 36 hours (Graph B.3.1.1, p.120). The initial 
increase observed accorded with results of experiments in vitro 
(Graph A.3.1.1, p. 99) in which amidolysis was potentiated by the 
presence of alkali-modified X- and i -carrageenan fractions.v a
Kinin-releasing activity of carrageenan was also observed iri vivo 
by Ratnoff (1966) and in vitro by Schwartz and Kellermeyer (1969) 
and Kindness (1979). This effect was observed to be dependent on 
Factor XII, prekallikrein and HMWK (van der Graaf, Koedam and Bouma, 
1983). Therefore, it may be inferred that the kallikrein-carrageenan 
response involves a complex inter-relationship, possibly through 
protein macromolecular alignment in order to achieve activation 
of the kallikrein-kinin pathway. The provision of a negatively- 
charged surface with a suitable molecular architecture would form the 
basis for Factor XII activation. The fact that this activity is 
a charge effect was shown by Kindness (1979) when it was found that 
kinin production was inhibited when the galactan sulphate negative 
charges were blocked by positively charged Polybrene (hexa-dimethrine 
bromide).
The structure of the polymer may be important when considering 
charge density "gaps” along a polyelectrolyte chain. The presence of 
these gaps may considerably decrease the possibility and strength of 
protein binding (Cifonelli, 1974). The type of gel network that 
l-carrageenan forms may cause masking of the negative charges, resulting
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in charge density gaps; therefore, the probability of protein inter­
actions along the chain length may be reduced compared to those possible 
when the less helical, or gel-like structure of the alkali-modified 
X-carrageenan is involved. The l- and K-carrageenan structures 
would therefore depend on chain linking sites for protein interaction 
(Introduction, p. 8).
The process of kallikrein formation is strictly regulated by 
certain plasma proteinase inhibitors. The neutralisation of plasma 
kallikrein may be brought about by Cl inhibitor (Ratnoff £t al., 1969; 
Gigli et^  al_. , 1970) a2-macroglobulin (Harpel, 1970; Fritz et^  al_., 1972)
t t
and antithrombin III (Burrowes, Habel and Movat, 1975; Vennerod and
t l  I t
Laake, 1975), although AT III has little or no effect unless heparin is 
present (van der Graaf, Koedam and Bouma, 1983).
In summary, the amidolytic activity catalysed by prekallikrein is 
initially increased up to 4 hours post carrageenan dose but is 
inhibited after 12 hours,returning to control values at 36 hours. In 
vitro, only the alkali-modified X-carrageenan and i-carrageenan causes 
an increase in prekallikrein-catalysed amidolysis. These effects may be 
related to the ability of galactan sulphates to bind to prekallikrein 
inhibitors, possibly resulting in the exposure of an active site.
For prekallikrein activation, there are requirements for Factor XII, 
HMWK, prekallikrein and a negatively charged surface, and the galactan 
sulphate may initiate the complex formation. This effect may, however, 
be blocked by antiproteinase-polymer macroion complex formation, 
resulting in inhibition of the kallikrein-kinin pathway.
In the study of Factor Xll-mediated responses,it has been shown 
that many of the component parts of the coagulation cascade are found 
in association with the blood platelet surface (Harfenist et al., 1981).
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Hence, not only has Factor XII been observed to be on the platelet 
surface but also other proteins such as fibrinogen. Also, the 
platelet contains granules capable of releasing their contents which 
would have a synergistic effect on thrombus formation (Introduction, 
p. 30). Hence, the interaction of carrageenans with platelets and 
possible platelet responses was investigated.
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4 .  P l a t e l e t  a g g re g a t io n  s tu d ie s
Heparin and the carrageenan fractions had little or no effect on 
rat platelets in vitro. When viewed microscopically, platelets pre­
incubated with high carrageenan concentrations were of normal discoid 
shape. Small agglutinates of platelets were seen, but no shape 
change or release reaction had occurred.
In view of the findings that carrageenan aggregates platelets in 
other species (MacMillan and Sim, 1970), the influence of the galactan 
sulphates in the presence of extracellular platelet aggregating 
compounds, namely adenosine 5*diphosphate (ADP) and thrombin, were 
studied. Platelets were incubated with galactan sulphates before 
the addition of the aggregating agent. A concentration of ADP (10 yM) 
which produced a reversible aggregation response was used. No signifi­
cant change in the aggregation response was observed in the presence 
of either heparin or carrageenan and microscopic analysis showed only 
small agglutinates of normal discoid platelets.
ADP induced platelet aggregation in most animal species, but 
the degree to which this occurred varied widely (Tomikawa et^  ail. ,
1978; MacMillan and Sim, 1970). In humans, baboon, cat, dog, horse 
and guinea pig blood, low concentrations of ADP (less than 2 yM) 
induced irreversible biphasic aggregation, whilst at the same, and 
much higher concentrations Cgreater than 2 yM), mouse, rat and rabbit 
platelets underwent reversible aggregation (Constantine, 1966;
MacMillan and Sim, 1970; Nun, 1981). These results accord with those 
reported in this thesis.
Rat platelets, when stimulated to aggregate by thrombin (1.0 NIH 
U ml "S , form a thrombus rapidly. At this concentration, a distinct
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biphasic response was recorded (Graph A.4.3.1, p. 101). Heparin 
greatly reduced thrombin-induced aggregation, even at low heparin 
concentrations (0.001 mg ml 1) (Graph A.4.3.1, p. 101). Alkali- 
modified X-carrageenan showed inhibition of aggregation at 0.001 
mg ml 1, l-carrageenan above 0.10 mg ml 1 and the K-carrageenans 
inhibited at 1.0 mg ml * (Graphs A.4.3.2 to A.4.3.6, p. 102 to 106).
In ex vivo assays, carrageenan fractions induced thrombocytopenia, 
with platelet counts decreasing to a minimum at 12 hours post dose (Graph 
B.4.1.1, p. 122). Carrageenan may induce rupture of the cell surface 
or adhere to the platelet surface to promote removal by the liver. 
Carrageenan at high concentrations (200 mg kg "S is known to induce 
disseminated intravascular coagulation, a condition which greatly 
reduces platelet numbers and results in severe damage to areas of 
blood stasis such as ears, tail and feet of the rat (Kindness - personal 
communication).
Alkali-modified X-carrageenan and l-carrageenan, when administered 
in vivo, inhibited platelet aggregation induced by both ADP and thrombin. 
ADP-induced aggregation was inhibited by the alkali-modified X-carrageenan 
over a 4-36 hour period, while l-carrageenan-treated animal plasma 
showed a delay before onset of inhibition at 6 hours (Graph B.4.2.2, 
p. 124).
Platelets have been shown to have ADP and thrombin receptors present 
on the cell surface, and Harfenist £t slL. (1981), showed that, in 
rabbits, platelets stimulated with ADP possessed fibrinogen binding 
sites. This suggests that ADP binds to platelets and induces a 
membrane structural change resulting in the exposure to specific and 
saturable receptors for fibrinogen. Prevention of fibrinogen binding 
to platelets by inhibitors could result in disaggregation and
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dissociation of bound fibrinogen (Harfenist et^  al., 1981). Fibrinogen 
would appear to act as an adhesive, binding platelets to one another 
and this reinforces the concept that fibrinogen plays an important 
part in the initiation of ADP-induced aggregation. This phenomenon 
may also explain the thrombocytopenic effects observed in carrageenan 
injected rats.
In the presence of carrageenan ex vivo, ADP aggregation was 
greatly inhibited, although ill vitro the carrageenans did not affect 
ADP-induced aggregation. A possible explanation of this effect is 
that the carrageenan may directly adsorb onto the platelet surface, thus 
preventing proteinase activity and the platelet-platelet interactions 
necessary for aggregation. Alternatively, since fibrinogen is a 
cofactor for ADP-induced aggregation, the carrageenan may act in a 
polyelectrolyte manner and bind to the fibrinogen molecule. Calcium 
is required for the final part of the coagulation cascade, and calcium 
ions are known to stabilise polyelectrolyte-protein complexes by 
neutralising free sulphate esters rather than taking an active part 
as a bridging cation (Lin, 1977). Also, the overall tertiary structure 
of the protein may allow a good "fit" into the polyelectrolyte structure 
as possibly occurs in the case of heparin-AT III complexes (Hopwood 
jet aT., 1976). Fibrinogen may also undergo conformational changes 
when the polymer is bound to the galactan sulphate fractions. This may 
be due to the highly charged carrageenan interacting with an oppositely 
charged region at the active site of fibrinogen. This would result in 
inhibition of fibrinogen activation and subsequent inhibition of ADP- 
induced aggregation.
Rat platelets, when stimulated by ADP, undergo reversible aggrega­
tion. Once the platelets disaggregate they may be further stimulated
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to aggregate with ADP, illustrating that the ADP does not permanently 
alter the platelet surface.
Thrombin-induced platelet aggregation was inhibited by carrageenans 
both in vitro and ex vivo. These results may be explained by the 
observed results of experiments in which heparin potentiates AT III 
in vitro, together with previous results of in_ vitro experiments on 
AT Ill-depleted plasma (Graph A.1.8.1, p.87) . The influence of heparin 
on thrombin was found to be dependent on the presence of AT III 
(Graph A.1.8.1, p. 87). These results suggest the formation of a 
heparin-AT III complex which inhibits thrombin activity and may act to 
protect platelets from aggregation by thrombin. It may be hypothesised 
that the heparin interaction with AT III present at the platelet surface 
greatly inhibits thrombin activation, and that a similar but weaker 
reaction occurs with carrageenan and AT III. These reactions may 
also explain why carrageenan itself does not induce platelet aggrega­
tion.
Carrageenan may interfere with platelet aggregation by a purely 
physical effect, in which platelet-associated calcium ions form 
neutralising bridges between the negatively-charged phospholipid 
and polyelectrolyte. The more flexible the polyelectrolyte, the more 
"coating*' ability it has; thus the alkali-modified X-carrageenan 
would be more efficient than the 1- or K-carrageenan fractions.
This was suggested in this study but could not be the only reason for 
ADP platelet aggregation effects since ADP aggregation iii vitro 
was not affected by the presence of carrageenan.
The platelet adhesiveness studies ex vivo again illustrate the 
potential of alkali-modified X-carrageenan and l-carrageenan as
1 6 5 .
anti-platelet compounds. Platelet adhesiveness was found to decrease 
to a minimum at 4 hours after administration of either carrageenan 
(Graph B.4.4.1, p. 133). For each time period, the platelets were 
examined microscopically, and all platelets from 1 -carrageenan- 
treated animals were observed to be normal. The alkali-modified X- 
carrageenan-treated platelets ex vivo were found to have a granular 
appearance at 4 hours but no pseudopodia were evident, and there was 
no evidence of adherence or aggregation. This effect was transient, 
since platelets viewed at 6 hours had a normal shape and were clearly 
visible by light microscopy at this stage.
The mechanism of this phenomenon is unclear, but it may be postulated 
that carrageenan is bound to the platelet surface, and may interfere 
with the uptake of the dye used in the experiment. The 4 hour response 
may be an indication of maximal carrageenan uptake, as illustrated 
by the functional clotting assays. This theory assumes that 
carrageenan binds to platelets in a manner similar to heparin (Gogstad, 
Solum and Knitness, 1983).
The delay in onset of inhibition by i-carrageenan was observed 
in most assays carried out. The alkali-modified X-carrageenan inhibited 
coagulation and had an anti-platelet effect earlier in the time course 
than i-carrageenan. Alkali-modified X-carrageenan may be taken up more 
readily by the peritoneal blood circulation than the more gel-like 
1-carrageenan. Alternatively, the lower charge density of l-carrageenan 
may reduce the possibility of protein alignment. Although each poly­
electrolyte has a high sulphate content, the availability and 
orientation of these groups is important. Also, as with the heparin- 
AT III complex already discussed (p. 153), a set configuration of 
disaccharide repeat units may be required for protein-carrageenan
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i n t e r a c t i o n .
In summary, carrageenans ijn vitro induced no aggregation, as 
well as having no effect on ADP-induced aggregation. Thrombin- 
induced aggregation was inhibited both in vitro and ex vivo by 
carrageenans, an effect which may occur via direct physical binding 
of carrageenan to the platelet surface or via interaction with platelet 
membrane-bound AT III to form an active complex. ADP-induced aggregation 
ex vivo was inhibited by carrageenan, possibly via fibrinogen- 
carrageenan complex formation.
Delay of onset of the inhibitory effect on aggregation may be a 
reflection of the physical nature of the carrageenans, with the 
alkali-modified X-carrageenan having an effect earlier in the time 
course than i-carrageenan. Both carrageenans ex vivo caused platelet 
thrombocytopenia and inhibited platelet adhesiveness, possibly due 
to carrageenan-platelet complex formation via calcium bridges.
It may be possible for a carrageenan-immunoglobulin interaction to 
take place where the immunoglobulin acts as an aggregating agent. Thus, 
the next stage in the investigation was to examine carrageenan-immuno­
globulin interactions.
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5. The immune system
Carrageenans have been used frequently as tools to study the 
immune response and the reticuloendothelial system. Few investi­
gators, however, have tried to relate the immune response to 
carrageenan-inducedFactor Xll-mediated haemostatic responses. The 
nature and magnitude of the effects of carrageenans were found to be 
dependent on both the route of injection and the form and purity of the 
material. In this study, the i,p. route of administration was used 
to allow correlation with the coagulation studies and assay results 
showed this route to give a stronger immunosuppressive effect over 
other routes (Cruickshank, personal communication). The characterised 
carrageenans were used to investigate their effects on the immune system 
but alkali-modified A-carrageenan was observed to have little immuno­
suppressive effect in the rat. Immunosuppression was found with all 
concentrations of i-carrageenan but maximally at 40 mg kg * when 
injected 24 hours prior to antigen, as shown by the dose response curve 
(Graph B.5.2.1, p. 137). The time of carrageenan administration in 
relation to antigen suggested that the carrageenan must exert an 
effect on the afferent limb of the immune system and not on the antibody 
producing B lymphocytes. The carrageenan may act at an early stage 
in the processing of the antigen by macrophages or in the macrophage- 
lymphocyte interaction (Lake, Bice and Schwartz, 1971).
A repeat of this study revealed considerable variability in 
responses, both to antigen alone and to the effects of carrageenan on 
the immune response. The reasons behind these variable responses remain 
unknown.
Rats injected with 40-60 mg kg 1 i-carrageenan i,p. developed 
certain pathological conditions. In all animals the caudate lobe of
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the liver was enveloped in a loosely bound capsule, and small plaques 
of the same material were loosely adherent to the liver surface. 
Microscopic examination of these plaques showed that a high percentage 
of the cell population consisted of actively proliferating fibroblasts 
containing carrageenan. Large macrophages containing carrageenan 
were seen by staining the preparation with corphosphine so that the 
presence of acid mucopolysaccharides on the cell surfaces was 
indicated as a light orange colour; large areas of bright orange were 
considered to represent the presence of carrageenan. The sac surrounding 
the caudate lobe of the liver consisted of a mesoendothelial sheath 
containing a proliferating mass of connective tissue. Many macrophages 
contained carrageenan globules coalescing around the nucleus, while 
other macrophages had actively undergone cell fusion. Cellular 
debris suggested that some macrophage destruction had occurred.
Immediately below the mesoendothelial sheath, dense masses of 
carrageenan were present around which macrophages were seen to 
aggregate.
The inflammation within the duodenum was also studied histologically. 
The circular musculature was seen to be intact but the inflammatory 
response had induced a proliferation of connective tissue similar to 
that of an epitheloid granuloma. This region contained microvascula­
ture into which many polymorphonuclear leucocytes had migrated. As 
in the liver, there was evidence of cell fusion and carrageenan 
uptake by both macrophages and fibroblasts.
No such pathological changes, but substantial immunosuppression, 
was evident at 20 mg kg 1 and for all further studies this concentration 
of l-carrageen was used.
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F in a lly , to evaluate the e ffec t of time of carrageenan adminis­
tration in relation to antigen, \-carrageenan was injected i,p. 
pre- and post-SRBC. Variability in the response was observed, and 
by using regression analysis no relationship was determined.
These results remain somewhat of an enigma, since in all cases the 
animals were of the same sex, breeding stock and were maintained 
under the same housing conditions and diet; all these factors can 
affect immunoglobulin levels.
Carrageenan has been previously described as an irritant which is 
toxic to macrophage, resulting in eventual cell death in vitro 
(Allison, Harrington and Birbeck, 1966; Cateinzaro, Schwartz and 
Graham, 1971). Recently, however, administration of carrageenan to 
the lung illustrated that an increase in lung macrophage longevity 
occurred (Bowers, Stapleton and Lew, 1983). These authors observed 
that carrageenan induced an inflammatory response which was character­
ised in its early stages by immediate polymorphonuclear leucocyte 
infiltration. After 2 days the polymorphs were replaced by macrophages 
bearing carrageenan. Macrophages, which readily take up carrageenan, 
swell due to the inability of the cells to degrade the carrageenan 
(Pugh-Humphreys, personal communication). Rupture of some macrophages 
in the peritoneum was observed in the present study, with the 
migration of cellular material to the liver region resulting in the 
formation of adherent plaques. Within these plaques large macrophages 
containing carrageenan or other polysaccharide were evident. These 
macrophages may have remained viable or may be a secondary phase 
sequesting cellular debris and carrageenan. The incorporation 
of carrageenan into macrophages without cell death may result in 
increased macrophage longevity as initially hypothesised by Spector
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(1974) and may be the mechanism of maintained inflammation. These 
macrophages may be prevented from leaving the peritoneum by purely 
physical characteristicsbecause carrageenan uptake into the macrophage 
lysosomes causes an increase in cell size.
Kindness (personal communication) showed that, at high carrageenan 
concentrations, rat tail, ear and paw damage occurred primarily in 
K-carrageenan-treated animals. Such damage was also observed in rat 
by Thomson et^  atl. (1976) using potassium carrageenan (50 mg per animal) . 
Clearly, however, the underlying cause of such damage is disseminated 
intravascular coagulation (DIC) caused either by a direct effect of 
carrageenan on platelets, inducing thrombocytopenia (Graph B.4.1.1, p. 
122), or by an effect of carrageenans on rat red cell membranes (Pittz, 
Golberg and Coulston, 1975).
Girman et _al. (1976) found that FDPs, when administered at the 
same time as, or 24 hours after, antigen, induced immunosuppression 
in vivo. However, in the present study, i-carrageenan inhibited 
fibrinolysis (Graph B.2.1.1, p. 115) and therefore no relationship 
between FDP induction and the observed immunosuppression can be 
suggested.
When macrophages encounter inflammatory stimuli in vivo they 
respond by releasing a number of products which may account for the 
central role that these cells have in chronic inflammatory diseases 
(Davies and Allison, 1976).
Active phagocytosis induces the production of a lymphokine called 
Interlukin 1. This interacts with the circulating T cells which in 
turn are stimulated to produce Interlukin 2 which acts to suppress 
B cell immunoglobulin synthesis. Since SRBC are T cell-dependent
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antigens this may have a direct relationship to the suppressive 
effects observed in this study (Watson, Mochizuki and Gillis, 1980; 
Oppenheim and Gery, 1982; Altman, 1982).
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6. Lipoprotein studies
Lipoproteins were separated from plasma obtained from carrageenan- 
treated rats by density ultracentrifugation. The concentration of 
lipoprotein was estimated using a cholesterol assay and results 
illustrated on Graphs B.6.1.1 to B.6.1.4 (p. 143 to p. 166) show 
that alkali-modified X-carrageenan (20 mg kg 1) caused an increase 
in VLDL and LDL concentrations at 12 hours post dose while not 
affecting IDL and HDL. With i-carrageenan, LDL concentrations were 
increased but VLDL, IDL and HDL concentrations were not significantly 
affected.
Of the lipoproteins, VLDL contain least cholesterol and as the 
density of the lipoprotein increases cholesterol content also increases.
This phenomenon was found in this study when control values over the 
time course were found to be 6.1 ± 0.7 mg 100 ml 1 serum in VLDL 
to 30.4 ± 1.8 mg 100 ml”1 with HDL (Graphs B.6.1.1 and B.6.1.4, p. 143 
and p. 146).
The alkali-modified X-carrageenan appears initially to cause the 
release of lipoprotein lipase from surface-bound receptors in peripheral 
tissue in a heparin-like manner. Heparin, when administered i .v ., showed 
antilipemic activity 10 minutes after injection, an effect which has 
been shown to last from 30 minutes to 2 hours (Mahadoo, Wright and 
Jaques, 1981; Bianchini et al., 1982). The action of heparin appears 
to be mediated through the release of lipoprotein lipase from endothelial 
receptors, thus changing the site of lipoprotein hydrolysis from 
limited segments of the capillary bed to circulating blood (Engelberg,
1978). Heparin then prevents lipoprotein lipase binding to the receptors 
on thd cell surface by occupying the receptor site (Goldstein et al_., 1976) .
173.
The unusually high concentrations of VLDL and IDL observed
with alkali-modified X-carrageenan at 0 and 2 hours were unexpected. 
Comparison with control values suggest that the animals used had 
high levels of VLDL and IDL similar to these observed prior to 
feeding of a high cholesterol diet. For every experiment the animals 
were starved for no less than 24 hours prior to carrageenan injection, 
and administration of polysaccharide was always carried out in the 
early morning. The significant decrease to control values at 4 hours 
suggest lipoprotein lipase activity, but concomitant LDL or HDL 
increases were not observed (Graphs B.6.1.3 and B.6.1.4, p. 146 and 
p. 147).
Rats are unique in that they have low LDL levels due to rapid 
clearance of this lipoprotein by the liver (Lasser crt aJL. , 1973) .
The liver plays an important part in rat sterol synthesis, while in 
other species studied (rabbit, guinea pig, hamster and monkey) the 
extrahepatic tissues are quantitatively more important (Koelz c*t al. , 
1982). The LDL turnover is relatively rapid with a reported half life 
of 4.3-8.5 hours (Hay elt jal. , 1971) while plasma cholesterol is 
carried by the HDLs (Lasser ejt al^ . , 1973). It should be noted, 
however, that LDL harvested from rat serum by conventional ultra­
centrifugation techniques may be contaminated with HDL, and quantitative 
errors may result in the measurement of LDL concentrations. Analysis 
of contamination could be carried out by separation of the apoproteins 
to find levels of HDL apoprotein E .
The i-carrageenan results show that little effect was observed on 
VLDL concentrations, although a small but significant peak was observed 
with IDL at 6 hours (Graph B.6.1.1 and B.6.1.2, p. 144 and p. 145).
An increase in IDL may occur because lipoprotein lipase activity on
174.
VLDL causes a transient increase on IDL levels. The effect seen 
at 6 hours would correspond to x-carrageenan uptake, as found 
by the functional clotting assays. The rise in IDL, although signifi­
cant, was sufficiently small that no direct decrease in VLDL levels 
may be recorded. However, the LDL level was increased at 6 hours, 
suggesting that accumulation of these lipoproteins may be occurring 
(Graph B.6.1.3, p. 146). This hypothesis may be countered by 
the fact that the half-life of LDL is 4-8 hours while that of HDL 
is 8-11 hours (Lasser et_ al_., 1973) . Hence some other mechanism must 
be influencing these lipoproteins causing an increase in their concentration.
It may be that the carrageenan promotes synthesis of LDL by the 
liver, a situation found to occur in rooster by Behr elb jil. (1981).
Similarly, sulphated polysaccharides could bind lipoproteins by ionic
tf
interactions (Laurent, Waserson and Obrink,1969). This may cause 
a retention of LDL by the circulation since receptor sites on the 
liver may no longer recognise the LDL-polyelectrolyte complex as 
containing LDL. Thus, l-carrageenan may bind IDL and LDL at the 
point of maximum carrageenan uptake due to its gel network structure 
and ionic binding properties. Rapid removal of the carrageenan would 
occur within the 24 hour period, as reflected by the functional 
assays, thus returning lipoprotein concentrations to normal. The 
possibility that sulphated GAGS bind LDL was also suggested by Donnelly,
Di Ferrante and Jackson (1978).
It has also been shown that the presence of glycosaminoglycans 
promotes physical changes in LDL (Bihari-Varga, Sztatisz and Gal, 1981).
At body temperature, LDL is in solution, but on addition of glycos- 
aminoglycan a complex forms between the glycosaminoglycan and LDL, 
rendering the LDL crystalline. This may possibly result in decreased
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mobility, increased resistance to enzymes and possible deposition 
on artery walls. If, however, a significant amount of HDL is 
present the GAG-LDL complex remains in solution. The mechanism of 
this phenomenon is not fully understood (Bihari-Varga, Sztatisz and 
Gal, 1981).
These results suggest that instead of polysaccharides having an 
antilipemic effect they may be an additional risk factor for athero­
sclerosis. This may be true for humans, but the induction of an 
atherosclerotic state in rats may be difficult, due to the fact that 
the above interactions rely on LDL binding. As previously stated,
LDL in rats is rapidly cleared and cholesterol is transported by 
HDL, which probably has less affinity for polysaccharide due to a 
potential lower ionic interaction. Hence the induction of an athero­
sclerotic state may be prevented by this unique LDL removal system 
(Lasser ejt a^. , 1973) .
The effect of the alkali-modified X-carrageenan occurs principally 
on the VLDL and IDLs, with a rapid reduction in VLDL s at 4 hours 
but a rise at 12 hours (Graph B.6.1.1, p. 144). The alkali-modified 
X-carrageenan may act in a similar manner to heparin by releasing 
lipoprotein lipase and by binding to hepatocytes to facilitate the 
uptake of the remnants produced by lipase activity (Goldstein et^  a]L., 
1976).
As the carrageenans may act in a heparin-like manner to cause 
lipoprotein lipase release from the endothelium, it may be presumed 
that lipase activity would become exhausted, resulting in an increase 
in VLDL concentration (Graph B.6.1.1, p. 144).
In summary, the initial high concentrations of VLDL and IDL 
found in the alkali-modified X-carrageenan-treated animals require
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further study. The alkali-modified A-carrageenan was shown to have 
an antilipemic effect, possibly due to the release of lipoprotein 
lipase from the endothelial cells induced by carrageenan competitive 
binding. An increase in VLDL concentrations at 12 hours may reflect 
a lipase exhaustion and retention of the VLDL concentration in the 
circulation. Little or no effect was observed on the other lipoprotein 
concentrations.
1-Carrageenan was found to affect primarily the LDL and HDL 
concentrations and it may be postulated that this occurs by an 
ionic interaction between the carrageenan and the lipoproteins, possibly 
causing a change in the physical behaviour of the lipoprotein preventing 
removal by the liver.
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VI CONCLUSION
The proteinase systems of blood which mediate inflammation 
and haemostasis, that is, the kallikrein-kinin, fibrinolytic and 
coagulation pathways together with the blood platelets,are usually 
considered in isolation, perhaps because of the differing techniques 
initially applied to their study and because it was conceptually 
easier to consider them separately. With increasing recognition 
of the complexity of the systems has come an appreciation of their 
inter-relationships, although the functions of the various points of 
interconnection are still being studied.
The pathways studied within this thesis are principally activated 
by one proteinase, Factor Xlla, which in concert with HMWK and pre- 
kallikrein forms the foeal point of this study. As Figure 2.8.1, p. 35 
illustrates, the pathways are regulated by positive and negative 
feedback mechanisms arising from, and inter-relating with, other pathways 
This results in a steady state in which vessel potency and blood 
fluidity is maintained.
Carrageenans are anionic polyelectrolytes, which in physiological 
conditions of pH 7.4 and ionic strength of 0.15 mS cm \  may bind 
some of the many plasma proteins that have a net positive charge under 
these conditions. Several factors are important in this binding, such 
as the three-dimensional shape and gel-forming abilities of the 
galactan sulphates together with their electrostatic and hydrogen 
bonding properties. Alignment of the protein may not be total, and 
intermediate degrees of association may occur. Ions present within 
the plasma may be not only required for the binding between positive 
and negative charged components but may also stabilise complexes which
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form by binding to unbound charged groups on either molecule. Alterna­
tively, these cations may act as bridges between two negatively- 
charged units such as carrageenan and platelet phospholipid or the 
complexes required for coagulation factor activation.
In summary, the important features for charge interaction are 
the concentration and mixing ratios of the polyanion and polycation, 
the pH, the concentration and charge of electrolytes, the charge 
density, nature, spacing and stereochemistry of the charged groups, 
and the molecular weights of the polymers.
Alkali-modified X-carrageenan and \-carrageenan both inhibited 
in vitro and ex vivo coagulation, through inhibitory effects on Factor 
Xlla and thrombin. These effects may be exerted partially via inter­
actions with antiproteinase such as AT III. In vitro K-carrageenan 
had little or no effect on coagulation but had potent fibrinolytic 
effects, results not found ex vivo with any fraction. In contrast, 
the carrageenans studied ex vivo inhibited fibrinolysis.
Carrageenans alone did not affect platelets, nor did they affect 
ADP-induced aggregation iri vitro but administration of carrageenan 
to rats inhibited ADP-induced aggregation. Aggregation effects due 
to thrombin were inhibited both in_ vitro and ex vivo,an effect which 
was maximal at 4-12 hours post dose. Carrageenans ex vivo also 
induced thrombocytopenia and reduced platelet adhesiveness. The ex vivo 
response to carrageenan was found to be time dependent. The onset 
of the response may reflect the chemical nature of the polymers with 
the alkali-modified X-carrageenan exerting its effect more rapidly than 
the l-carrageenan. Again this may be an inherent property of the 
absorption and distribution of these polymers from the peritoneum.
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Of the two fractions studied ex vivo, alkali-modified X-carrageenan 
affected lipoprotein levels probably through the displacement of 
lipoprotein lipase from the endothelial cell surfaces. In contrast, 
while i-carrageenan had little effect on lipoprotein concentrations, 
this fraction was found to be immunosuppressive while the alkali- 
modified X-carrageenan had no effect.
The interaction processes involved in these pathways is complex 
but results obtained within this thesis illustrate that carrageenans 
may act to modify the following systems: the intrinsic pathway of 
coagulation; kallikrein-kinin pathway; fibrinolytic pathway; platelet 
responses; and immunoglobulin synthesis in response to antigen.
Factor XII activation by carrageenan occurs in conduction with the 
fibrinolytic and kallikrein systems but in the coagulation system this 
effect is masked by the effect of carrageenan at other areas of the 
coagulation pathway. Several proteinase inhibitors are common to the 
pathways investigated and the carrageenans could influence these 
proteins to modify their activity. In the case of AT III, a direct 
interaction with carrageenan may be postulated although this did not 
account for the total anticoagulant effect obtained in the thesis.
Further studies are required to pinpoint the exact areas at 
which carrageenan exerts an effect on the systems studied within this 
thesis.
In conclusion, by careful selection of concentration, structure, 
mode of injection and time course,these galactan sulphates may serve 
as usefulexploritory tools in the elucidation of polyelectrolye- 
protein interactions.
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